

**WEST**

Generate Collection

Print

L4: Entry 14 of 15

File: DWPI

Sep 25, 1997

DERWENT-ACC-NO: 1997-479907

DERWENT-WEEK: 199744

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Protein comprising CRAF1-b domain capable of inhibiting CD40 mediated cell activation - useful to treat conditions characterised by aberrant or unwanted level of CD40 mediated intracellular signalling

Basic Abstract Text (2):

USE - The protein and CRAF1 peptide inhibit CD40 ligand activation of cells expressing CD40 on their surface, particularly by introducing the nucleic acid molecule into the cells, useful to treat conditions characterised by an aberrant or unwanted level of CD40 mediated intracellular signalling, such as organ rejection in a subject receiving transplant organs, e.g. kidney, heart or liver, or a CD40 dependent immune response in a subject receiving gene therapy. The condition may be an allergic response, e.g. hay fever or a penicillin allergy, and a CD40 dependent immune response may be an autoimmune response in a subject suffering from an autoimmune disease, e.g. rheumatoid arthritis, Myasthenia gravis, systemic lupus erythematosus, Graves' disease, idiopathic thrombocytopaenia purpura, haemolytic anaemia or diabetes mellitus, or a drug induced autoimmune disease, e.g. drug induced lupus, psoriasis or hyper immunoglobulin E syndrome. The autoimmune response comprises induction of CD23, CD80 upregulation, rescue from CD95 mediated apoptosis, rescue from apoptosis in a subject undergoing chemotherapy against a tumour or autoimmune manifestations of an infectious disease, e.g. derived from Rieter's syndrome, spondyloarthritis, Lyme disease, HIV infections, syphilis or tuberculosis.

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 15 of 15 returned.**

☐ 11. Document ID: US 20020127615 A1 WO 200053629 A1 AU 200035260 A US 6410710 B1

L4: Entry 11 of 15

File: DWPI

Sep 12, 2002

DERWENT-ACC-NO: 2000-587425

DERWENT-WEEK: 200262

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Novel tumor necrosis factor (TNF) receptor-associated factor deletion isoforms for identifying an agent that inhibits CD-40 mediated cellular signaling and for inhibiting e.g. rheumatoid arthritis and diabetes mellitus

INVENTOR: EYNDHOVEN, W V; LEDERMAN, S ; VAN EYNDHOVEN, W

PRIORITY-DATA: 1999US-0268544 (March 11, 1999), 2001US-0950902 (September 10, 2001)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020127615 A1	September 12, 2002		000	G01N033/567
WO 200053629 A1	September 14, 2000	E	170	C07K014/00
AU 200035260 A	September 28, 2000		000	C07K014/00
US 6410710 B1	June 25, 2002		000	C07H021/04

INT-CL (IPC): A61 K 35/00; A61 K 38/00; A61 K 48/00; C07 H 21/04; C07 K 14/00; C07 K 14/705; C12 N 9/00; C12 N 15/11; C12 N 15/63; G01 N 33/567

[Full](#) | [Title](#) | [Citation](#) | [Front](#) | [Review](#) | [Classification](#) | [Date](#) | [Reference](#) | [Sequences](#) | [Attachments](#)[KWC](#) | [Draw Desc](#) | [Clip Img](#) | [Image](#)

☐ 12. Document ID: WO 9912566 A1 AU 9895652 A NO 200001104 A EP 1011725 A1 CN 1278736 A KR 2001023787 A JP 2001515708 W AU 740981 B US 6440418 B1

L4: Entry 12 of 15

File: DWPI

Mar 18, 1999

DERWENT-ACC-NO: 1999-229142

DERWENT-WEEK: 200260

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: New humanized antibodies to human gp30

INVENTOR: BLACK, A; HANNA, N ; NEWMAN, R A ; PADLAN, E A

PRIORITY-DATA: 1997US-0925339 (September 8, 1997), 1995US-0554840 (November 7, 1995)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9912566 A1	March 18, 1999	E	121	A61K039/395
AU 9895652 A	March 29, 1999		000	
NO 200001104 A	May 8, 2000		000	C12P000/00
EP 1011725 A1	June 28, 2000	E	000	A61K039/395
CN 1278736 A	January 3, 2001		000	A61K039/395
KR 2001023787 A	March 26, 2001		000	A61K039/395
JP 2001515708 W	September 25, 2001		093	C12N015/09
AU 740981 B	November 15, 2001		000	A61K039/395
US 6440418 B1	August 27, 2002		000	A61K039/395

INT-CL (IPC): A61 K 39/395; A61 K 48/00; A61 P 3/10; A61 P 29/00; A61 P 37/02; A61 P 37/06; C07 H 21/04; C07 K 16/00; C07 K 16/18; C07 K 16/28; C12 N 5/10; C12 N 15/02; C12 N 15/09; C12 N 15/13; C12 P 0/00; C12 P 21/08

Full	Title	Classification	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------------	-------	--------	----------------	------	-----------	-----------	-------------

HTML	Draw Desc	Image
------	-----------	-------

☒ 13. Document ID: AU 200229200 A WO 9830240 A1 AU 9857097 A EP 948355 A1 NO 9903274 A CZ 9902444 A3 CN 1247472 A BR 9714523 A HU 200000833 A2 MX 9906439 A1 NZ 337072 A KR 2000070034 A JP 2001508441 W

L4: Entry 13 of 15

File: DWPI

Jun 27, 2002

DERWENT-ACC-NO: 1998-398804

DERWENT-WEEK: 200254

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Use of an anti-CD40 ligand compound - useful for, e.g. treating or inhibiting progression of nephritis in patient with immune complex disease

INVENTOR: KALLED, S L; THOMAS, D W

PRIORITY-DATA: 1997US-034673P (January 10, 1997), 2002AU-0029200 (March 28, 2002)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 200229200 A	June 27, 2002		000	A61K039/395
WO 9830240 A1	July 16, 1998	E	035	A61K039/395
AU 9857097 A	August 3, 1998		000	A61K039/395
EP 948355 A1	October 13, 1999	E	000	A61K039/395
NO 9903274 A	September 10, 1999		000	A61K000/00
CZ 9902444 A3	October 13, 1999		000	A61K039/395
CN 1247472 A	March 15, 2000		000	A61K039/395
BR 9714523 A	May 2, 2000		000	A61K039/395
HU 200000833 A2	July 28, 2000		000	A61K039/395
MX 9906439 A1	October 1, 1999		000	A61K039/395
NZ 337072 A	December 22, 2000		000	A61K039/395
KR 2000070034 A	November 25, 2000		000	A61K039/395
JP 2001508441 W	June 26, 2001		038	A61K045/00

INT-CL (IPC): A61 K 0/00; A61 K 39/395; A61 K 45/00; A61 P 13/12; A61 P 37/00; A61 P 37/06

Full	Title	Classification	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------------	-------	--------	----------------	------	-----------	-----------	-------------

HTML	Draw Desc	Clip Img	Image
------	-----------	----------	-------

☐ 14. Document ID: WO 9734473 A1 AU 9725939 A

L4: Entry 14 of 15

File: DWPI

Sep 25, 1997

DERWENT-ACC-NO: 1997-479907

DERWENT-WEEK: 199744

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Protein comprising CRAF1-b domain capable of inhibiting CD40 mediated cell activation - useful to treat conditions characterised by aberrant or unwanted level of CD40 mediated intracellular signalling

INVENTOR: CLEARY, A M; FRANK, D M ; LEDERMAN, S

PRIORITY-DATA: 1996US-026584P (September 18, 1996), 1996US-013820P (March 21, 1996), 1996US-016626P (May 1, 1996), 1996US-016659P (May 1, 1996)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9734473 A1	September 25, 1997	E	158	A01N001/02
AU 9725939 A	October 10, 1997		000	A01N001/02

INT-CL (IPC): A01 N 1/02; A01 N 43/04; A01 N 63/00; A01 N 65/00; A61 K 31/70; A61 K 35/14; A61 K 38/00; A61 K 39/00; G01 N 33/53

Full	Title	Classification	Abstract	Review	Classification	Date	Reference	Sequence	Attachments
------	-------	----------------	----------	--------	----------------	------	-----------	----------	-------------

Full	Drawings	Image
------	----------	-------

☐ 15. Document ID: WO 9717446 A2 AU 9711576 A WO 9717446 A3 NO 9802062 A EP 862630 A2 CN 1207127 A NZ 324500 A HU 9902327 A2 US 6001358 A JP 2000500334 W AU 717762 B KR 99067370 A

L4: Entry 15 of 15

File: DWPI

May 15, 1997

DERWENT-ACC-NO: 1997-281035

DERWENT-WEEK: 200260

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Humanised antibody capable of competing with, or derived from, murine 24-31 antibody - useful to modulate gp39 expression or inhibiting gp39/CD40 interaction

INVENTOR: BLACK, A; HANNA, N ; NEWMAN, R A ; PADLAN, E A

PRIORITY-DATA: 1995US-0554840 (November 7, 1995)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9717446 A2	May 15, 1997	E	106	C12N015/13
AU 9711576 A	May 29, 1997		000	C12N015/13
WO 9717446 A3	September 25, 1997		000	C12N015/13
NO 9802062 A	July 6, 1998		000	C07K000/00
EP 862630 A2	September 9, 1998	E	000	C12N015/13
CN 1207127 A	February 3, 1999		000	C12N015/13
NZ 324500 A	August 28, 1999		000	C07K016/46
HU 9902327 A2	October 28, 1999		000	C12N015/13
US 6001358 A	December 14, 1999		000	A61K039/395
JP 2000500334 W	January 18, 2000		098	C12N015/09
AU 717762 B	March 30, 2000		000	C12N015/13
KR 99067370 A	August 16, 1999		000	C12N015/13

INT-CL (IPC): A61 K 39/395; A61 P 1/04; A61 P 3/10; A61 P 11/06; A61 P 17/00; A61 P 17/06; A61 P 27/00; A61 P 29/00; A61 P 35/02; A61 P 37/00; A61 P 37/08; C07 K 0/00; C07 K 16/28; C07 K 16/46; C12 N 15/09; C12 N 15/13; C12 N 15/09; C12 R 1:91

Full Title Citation Front Review Classification Date Reference Sequences Attachments

RUMC Draw Desc Clip Img Image

Generate Collection

Print

Term	Documents
CD40L.DWPI,EPAB,JPAB,USPT,PGPB.	510
CD40LS.DWPI,EPAB,JPAB,USPT,PGPB.	2
CD40.DWPI,EPAB,JPAB,USPT,PGPB.	1548
CD40S	0
LIGAND.DWPI,EPAB,JPAB,USPT,PGPB.	68483
LIGANDS.DWPI,EPAB,JPAB,USPT,PGPB.	47337
GP39.DWPI,EPAB,JPAB,USPT,PGPB.	202
GP39S	0
ITP.DWPI,EPAB,JPAB,USPT,PGPB.	799
ITPS.DWPI,EPAB,JPAB,USPT,PGPB.	18
((CD40L OR CD40 ADJ LIGAND OR GP39)SAME (ITP OR THROMBOCYTOPENIA OR PURPURA)).USPT,PGPB,JPAB,EPAB,DWPI.	15

There are more results than shown above. [Click here to view the entire set.](#)

Display Format:

-

Change Format

[Previous Page](#)

[Next Page](#)

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 15 returned.**☐ 1. Document ID: US 20020127615 A1

L4: Entry 1 of 15

File: PGPB

Sep 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020127615

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020127615 A1

TITLE: TRAF-3 deletion isoforms and uses thereof

PUBLICATION-DATE: September 12, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lederman, Seth	New York	NY	US	
Eyndhoven, Winfried Van	Bellport	NY	US	

US-CL-CURRENT: [435/7.21](#); [435/183](#), [435/320.1](#), [435/325](#), [530/350](#), [536/23.2](#)[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KIMC](#) [Draw Desc](#) [Image](#)☐ 2. Document ID: US 20020072091 A1

L4: Entry 2 of 15

File: PGPB

Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020072091

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020072091 A1

TITLE: Death domain containing receptor 5

PUBLICATION-DATE: June 13, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ni, Jian	Rockville	MD	US	
Gentz, Reiner L.	Rockville	MD	US	
Yu, Guo-Liang	Berkeley	CA	US	
Rosen, Craig A.	Laytonville	MD	US	

US-CL-CURRENT: [435/69.1](#); [435/320.1](#), [435/325](#), [530/350](#), [536/23.5](#)[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[KIMC](#) [Draw Desc](#) [Image](#)☐ 3. Document ID: US 20020058029 A1

L4: Entry 3 of 15

File: PGPB

May 16, 2002

PGPUB-DOCUMENT-NUMBER: 20020058029  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20020058029 A1

TITLE: Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination

PUBLICATION-DATE: May 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hanna, Nabil	Rancho Santa Fe	CA	US	

US-CL-CURRENT: 424/131.1; 424/144.1

Full	Title	Citation	Print	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

Title	Draw Desc	Image
-------	-----------	-------

☐ 4. Document ID: US 20020031522 A1

L4: Entry 4 of 15

File: PGPB

Mar 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020031522  
PGPUB-FILING-TYPE: new  
DOCUMENT-IDENTIFIER: US 20020031522 A1

TITLE: TRUNCATED CRAFI INHIBITS CD40 SIGNALING

PUBLICATION-DATE: March 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
BALTIMORE, DAVID	BOSTON	MA	US	
CHENG, GENHONG	LOS ANGELES	CA	US	
YE, ZHENG-SHENG	NEW YORK	NY	US	
LEDERMAN, SETH	NEW YORK	NY	US	
CLEARY, AILEEN	NEW YORK	NY	US	

US-CL-CURRENT: 424/185.1; 435/63, 435/64, 435/7.2, 435/7.23, 530/324, 530/350, 530/358

Full	Title	Citation	Print	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

Title	Draw Desc	Image
-------	-----------	-------

☒ 5. Document ID: US 6440418 B1

L4: Entry 5 of 15

File: USPT

Aug 27, 2002

US-PAT-NO: 6440418  
DOCUMENT-IDENTIFIER: US 6440418 B1

TITLE: Methods of treating autoimmune diseases with gp39-specific antibodies

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Black; Amelia	Cardiff	CA		
Hanna; Nabil	Olivenhian	CA		
Padlan; Eduardo A.	Kensington	MD		
Newman; Roland A.	San Diego	CA		

US-CL-CURRENT: 424/154.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/144.1,  
424/153.1, 424/173.1, 530/387.1, 530/387.3, 530/388.1, 530/388.2, 530/388.22,  
530/388.7, 530/388.73, 530/388.75

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RMIC	Draw Desc	Image
------	-----------	-------

☐ 6. Document ID: US 6410710 B1

L4: Entry 6 of 15

File: USPT

Jun 25, 2002

US-PAT-NO: 6410710

DOCUMENT-IDENTIFIER: US 6410710 B1

TITLE: Nucleic acid encoding a TRAF-3 deletion isoform

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lederman; Seth	New York	NY		
Van Eyndhoven; Winfried	Bayside	NY		

US-CL-CURRENT: 536/23.5; 435/320.1, 536/23.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RMIC	Draw Desc	Image
------	-----------	-------

☐ 7. Document ID: US 6001358 A

L4: Entry 7 of 15

File: USPT

Dec 14, 1999

US-PAT-NO: 6001358

DOCUMENT-IDENTIFIER: US 6001358 A

TITLE: Humanized antibodies to human gp39, compositions containing thereof

DATE-ISSUED: December 14, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Black; Amelia	Cardiff	CA		
Hanna; Nabil	Olivenhian	CA		
Padlan; Eduardo A.	Kensington	MD		
Newman; Roland A.	San Diego	CA		

US-CL-CURRENT: 424/154.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/144.1,  
424/153.1, 424/173.1, 530/387.1, 530/387.3, 530/388.1, 530/388.2, 530/388.22,  
530/388.7, 530/388.73, 530/388.75, 536/23.53

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RMIC	Draw Desc	Image
------	-----------	-------



☐ 8. Document ID: EP 1101495 A1

L4: Entry 8 of 15

File: EPAB

May 23, 2001

PUB-NO: EP001101495A1

DOCUMENT-IDENTIFIER: EP 1101495 A1

TITLE: PREVENTIVES FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA

PUBN-DATE: May 23, 2001

## INVENTOR-INFORMATION:

## NAME

YAMAUCHI, TOSHIHIKO

YOKOHAMA, HIROMITSU

KOBAYASHI, SEIICHI

SETO, TOSHIO

## COUNTRY

JP

JP

US

JP

INT-CL (IPC): A61 K 45/00; A61 K 39/395; A61 P 7/04

EUR-CL (EPC): C07K016/28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: US 20020058029 A1 AU 200191037 A WO 200222212 A2

L4: Entry 9 of 15

File: DWPI

May 16, 2002

DERWENT-ACC-NO: 2002-479170

DERWENT-WEEK: 200254

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Treating an autoimmune disease, such as multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease, comprises administering a combination of immunoregulatory and B cell depleting activity antibodies

INVENTOR: HANNA, N

PRIORITY-DATA: 2001US-0954274 (September 18, 2001), 2000US-233607P (September 18, 2000), 2000US-257147P (December 22, 2000)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020058029 A1	May 16, 2002		022	A61K039/395
AU 200191037 A	March 26, 2002		000	A61P037/00
WO 200222212 A2	March 21, 2002	E	058	A61P037/00

INT-CL (IPC): A61 K 31/445; A61 K 38/13; A61 K 39/395; A61 K 47/48; A61 K 51/10; A61 P 37/00; A61 K 39/395; A61 K 39/395 ; A61 K 38:13; A61 K 31:445

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 10. Document ID: EP 1101495 A1 WO 200072882 A1

L4: Entry 10 of 15

File: DWPI

May 23, 2001

DERWENT-ACC-NO: 2001-061449

DERWENT-WEEK: 200130

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Preventives for idiopathic thrombocytopenic purpura comprising e.g. inhibitor of gp39 mediated contact dependent helper effector function on T cell surface

INVENTOR: KOBAYASHI, S; SETO, T ; YAMAUCHI, T ; YOKOHAMA, H

PRIORITY-DATA: 1999JP-0153383 (June 1, 1999)

## PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1101495 A1	May 23, 2001	E	000	A61K045/00
WO 200072882 A1	December 7, 2000	J	018	A61K045/00

INT-CL (IPC): A61 K 39/395; A61 K 45/00; A61 P 7/04

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KMC	Draw Desc	Image
-----	-----------	-------

[Generate Collection](#)[Print](#)

Term	Documents
CD40L.DWPI,EPAB,JPAB,USPT,PGPB.	510
CD40LS.DWPI,EPAB,JPAB,USPT,PGPB.	2
CD40.DWPI,EPAB,JPAB,USPT,PGPB.	1548
CD40S	0
LIGAND.DWPI,EPAB,JPAB,USPT,PGPB.	68483
LIGANDS.DWPI,EPAB,JPAB,USPT,PGPB.	47337
GP39.DWPI,EPAB,JPAB,USPT,PGPB.	202
GP39S	0
ITP.DWPI,EPAB,JPAB,USPT,PGPB.	799
ITPS.DWPI,EPAB,JPAB,USPT,PGPB.	18
((CD40L OR CD40 ADJ LIGAND OR GP39)SAME (ITP OR THROMBOCYTOPENIA OR PURPURA)).USPT,PGPB,JPAB,EPAB,DWPI.	15

There are more results than shown above. [Click here to view the entire set.](#)

**Display Format:**

-

[Change Format](#)[Previous Page](#)[Next Page](#)


\*Generation of this page has been interrupted by a request for another page

-

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD40L.DWPI,EPAB,JPAB,USPT,PGPB.	510
CD40LS.DWPI,EPAB,JPAB,USPT,PGPB.	2
CD40.DWPI,EPAB,JPAB,USPT,PGPB.	1548
CD40S	0
LIGAND.DWPI,EPAB,JPAB,USPT,PGPB.	68483
LIGANDS.DWPI,EPAB,JPAB,USPT,PGPB.	47337
GP39.DWPI,EPAB,JPAB,USPT,PGPB.	202
GP39S	0
SOLUBLE.DWPI,EPAB,JPAB,USPT,PGPB.	532481
SOLUBLES.DWPI,EPAB,JPAB,USPT,PGPB.	4524
ITP.DWPI,EPAB,JPAB,USPT,PGPB.	799
((CD40L OR CD40 ADJ LIGAND OR GP39)SAME (SOLUBLE) AND (INHIBIT\$ OR SUPPRESS\$ OR BLOCK\$ OR PREVENT\$ OR TREAT\$ OR THERAP\$) SAME (ITP OR THROMBOCYTOPENIA OR PURPURA)).USPT,PGPB,JPAB,EPAB,DWPI.	110

There are more results than shown above. [Click here to view the entire set.](#)

**Database:** 

**Search:**

L5

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

**DATE:** Wednesday, November 06, 2002   [Printable Copy](#)   [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<u>L5</u>	(cd40L or cd40 adj ligand or gp39)same (soluble) and (inhibit\$ or suppress\$ or block\$ or prevent\$ or treat\$ or therap\$) same (itp or thrombocytopenia or purpura)	110	<u>L5</u>
<u>L4</u>	(cd40L or cd40 adj ligand or gp39)same (itp or thrombocytopenia or purpura)	15	<u>L4</u>
<u>L3</u>	(cd40L or cd40 adj ligand or gp39) and (itp or thrombocytopenia or purpura)	242	<u>L3</u>
<u>L2</u>	(cd40L or cd40 adj ligand or gp39) and (inhibit\$ or suppress\$ or block\$ or prevent\$ or treat\$ or therap\$) same (alloimmun\$)	7	<u>L2</u>
<u>L1</u>	lazarus-alan\$	6	<u>L1</u>

END OF SEARCH HISTORY

**WEST**[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
CD40L.DWPI,EPAB,USPT.	251
CD40LS.DWPI,EPAB,USPT.	2
CD40.DWPI,EPAB,USPT.	956
CD40S	0
LIGAND.DWPI,EPAB,USPT.	56962
LIGANDS.DWPI,EPAB,USPT.	40379
GP39.DWPI,EPAB,USPT.	145
GP39S	0
SOLUBLE.DWPI,EPAB,USPT.	447337
SOLUBLES.DWPI,EPAB,USPT.	4183
ITP.DWPI,EPAB,USPT.	670
((CD40L OR CD40 ADJ LIGAND OR GP39)SAME (SOLUBLE) AND (INHIBIT\$ OR SUPPRESS\$ OR BLOCK\$ OR PREVENT\$ OR TREAT\$ OR THERAP\$) SAME (ITP OR THROMBOCYTOPENIA OR PURPURA)).USPT,EPAB,DWPI.	23

There are more results than shown above. [Click here to view the entire set.](#)

**Database:** US Patents Full-Text Database  
US Pre-Grant Publication Full-Text Database  
JPO Abstracts Database  
EPO Abstracts Database  
Derwent World Patents Index  
IBM Technical Disclosure Bulletins

**Search:**

L6

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

**DATE:** Wednesday, November 06, 2002   [Printable Copy](#)   [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=USPT,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L6</u>	(cd40L or cd40 adj ligand or gp39)same (soluble) and (inhibit\$ or suppress\$ or block\$ or prevent\$ or treat\$ or therap\$) same (itp or thrombocytopenia or purpura)	23	<u>L6</u>
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<u>L5</u>	(cd40L or cd40 adj ligand or gp39)same (soluble) and (inhibit\$ or suppress\$ or block\$ or prevent\$ or treat\$ or therap\$) same (itp or thrombocytopenia or purpura)	110	<u>L5</u>
<u>L4</u>	(cd40L or cd40 adj ligand or gp39)same (itp or thrombocytopenia or purpura)	15	<u>L4</u>
<u>L3</u>	(cd40L or cd40 adj ligand or gp39) and (itp or thrombocytopenia or purpura)	242	<u>L3</u>
<u>L2</u>	(cd40L or cd40 adj ligand or gp39) and (inhibit\$ or suppress\$ or block\$ or prevent\$ or treat\$ or therap\$) same (alloimmun\$)	7	<u>L2</u>
<u>L1</u>	lazarus-alan\$	6	<u>L1</u>

END OF SEARCH HISTORY

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 23 returned.**☐ 1. Document ID: US 6476195 B1

L6: Entry 1 of 23

File: USPT

Nov 5, 2002

US-PAT-NO: 6476195

DOCUMENT-IDENTIFIER: US 6476195 B1

TITLE: Secreted protein HNFGF20

DATE-ISSUED: November 5, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Komatsoulis; George	Silver Spring	MD		
Rosen; Craig A.	Laytonsville	MD		
Ruben; Steven M.	Olney	MD		
Duan; Roxanne D.	Bethesda	MD		
Moore; Paul A.	Germantown	MD		
Shi; Yanggu	Gaithersburg	MD		
LaFleur; David W.	Washington	DC		
Wei; Ying-Fei	Berkeley	CA		
Ni; Jian	Rockville	MD		
Florence; Kimberly A.	Rockville	MD		
Young; Paul	Gaithersburg	MD		
Brewer; Laurie A.	St. Paul	MN		
Soppet; Daniel R.	Centreville	VA		
Endress; Gregory A.	Potomac	MD		
Ebner; Reinhard	Gaithersburg	MD		
Olsen; Henrik	Gaithersburg	MD		
Mucenski; Michael	Cincinnati	OH		

US-CL-CURRENT: 530/350; 435/6, 435/7.1, 536/23.1[Full](#) [Title](#) [Citation](#) [Print](#) [Review](#) [Classification](#) [Data](#) [Reference](#) [Sequences](#) [Attachments](#)[HTML](#) [Draw Page](#) [Image](#)☐ 2. Document ID: US 6475987 B1

L6: Entry 2 of 23

File: USPT

Nov 5, 2002

US-PAT-NO: 6475987

DOCUMENT-IDENTIFIER: US 6475987 B1

TITLE: Tall-1 receptor homologues

DATE-ISSUED: November 5, 2002

## INVENTOR-INFORMATION:



NAME	CITY	STATE	ZIP CODE	COUNTRY
Shu; Hong-Bing	Denver	CO		

US-CL-CURRENT: 514/12; 435/69.1, 530/350, 536/23.5

Full	Title	Citation	Print	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RTS	Draw Desc	Image
-----	-----------	-------

☐ 3. Document ID: US 6475753 B1

L6: Entry 3 of 23

File: USPT

Nov 5, 2002

US-PAT-NO: 6475753

DOCUMENT-IDENTIFIER: US 6475753 B1

TITLE: 94 Human Secreted Proteins

DATE-ISSUED: November 5, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ruben; Steven M.	Olney	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		
Wei; Ying-Fei	Berkeley	CA		
Young; Paul	Gaithersburg	MD		
Florence; Kimberly	Rockville	MD		
Soppet; Daniel R.	Centreville	VA		
Brewer; Laurie A.	St. Paul	MN		
Endress; Gregory A.	Potomac	MD		
Carter; Kenneth C.	Potomac	MD		
Mucenski; Michael	Cincinnati	OH		
Ebner; Reinhard	Gaithersburg	MD		
Lafleur; David W.	Washington	DC		
Olsen; Henrik	Gaithersburg	MD		
Shi; Yanggu	Gaithersburg	MD		
Moore; Paul A.	Germantown	MD		
Komatsoulis; George	Silver Spring	MD		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/471, 435/69.4, 435/71.1, 530/350, 536/23.5

Full	Title	Citation	Print	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

RTS	Draw Desc	Image
-----	-----------	-------

☐ 4. Document ID: US 6472512 B1

L6: Entry 4 of 23

File: USPT

Oct 29, 2002

US-PAT-NO: 6472512

DOCUMENT-IDENTIFIER: US 6472512 B1

TITLE: Keratinocyte derived interferon

DATE-ISSUED: October 29, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 530/388.2; 435/331, 435/335, 435/7.92, 530/388.15, 530/389.2,  
530/391.3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 5. Document ID: US 6455040 B1

L6: Entry 5 of 23

File: USPT

Sep 24, 2002

US-PAT-NO: 6455040

DOCUMENT-IDENTIFIER: US 6455040 B1

TITLE: Tumor necrosis factor receptor 5

DATE-ISSUED: September 24, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wei; Ying-Fei	Berkeley	CA		
Ni; Jian	Rockville	MD		
Gentz; Reiner L.	Rockville	MD		
Ruben; Steven M.	Odenton	MD		

US-CL-CURRENT: 424/134.1; 424/139.1, 424/143.1, 424/178.1, 435/328, 435/334,  
435/7.21, 530/387.3, 530/387.9, 530/388.22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 6. Document ID: US 6440418 B1

L6: Entry 6 of 23

File: USPT

Aug 27, 2002

US-PAT-NO: 6440418

DOCUMENT-IDENTIFIER: US 6440418 B1

TITLE: Methods of treating autoimmune diseases with gp39-specific antibodies

DATE-ISSUED: August 27, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Black; Amelia	Cardiff	CA		
Hanna; Nabil	Olivenhian	CA		
Padlan; Eduardo A.	Kensington	MD		
Newman; Roland A.	San Diego	CA		

US-CL-CURRENT: 424/154.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/144.1,  
424/153.1, 424/173.1, 530/387.1, 530/387.3, 530/388.1, 530/388.2, 530/388.22,  
530/388.7, 530/388.73, 530/388.75

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

☐ 7. Document ID: US 6433147 B1

L6: Entry 7 of 23

File: USPT

Aug 13, 2002

US-PAT-NO: 6433147

DOCUMENT-IDENTIFIER: US 6433147 B1

TITLE: Death domain containing receptor-4

DATE-ISSUED: August 13, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		
Pan; James G.	Belmont	CA		
Gentz; Reiner L.	Rockville	MD		
Dixit; Vishva M.	Los Altos Hills	CA		

US-CL-CURRENT: 530/387.3; 424/178.1, 435/252.3, 435/254.11, 435/325, 435/69.1,  
530/300, 530/350, 530/402, 536/23.1, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

☐ 8. Document ID: US 6433145 B1

L6: Entry 8 of 23

File: USPT

Aug 13, 2002

US-PAT-NO: 6433145

DOCUMENT-IDENTIFIER: US 6433145 B1

TITLE: Keratinocyte derived interferon

DATE-ISSUED: August 13, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 530/351; 424/85.4, 435/7.1, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KM/C	Draw Desc	Image
------	-----------	-------

☐ 9. Document ID: US 6406867 B1

L6: Entry 9 of 23

File: USPT

Jun 18, 2002

US-PAT-NO: 6406867

DOCUMENT-IDENTIFIER: US 6406867 B1

TITLE: Antibody to human endokine alpha and methods of use

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/7.2; 424/130.1, 424/139.1, 424/141.1, 424/142.1, 424/158.1,  
530/387.1, 530/387.9, 530/388.1, 530/388.15, 530/388.24, 530/389.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

HTML	Draw Desc	Image
------	-----------	-------

☐ 10. Document ID: US 6403770 B1

L6: Entry 10 of 23

File: USPT

Jun 11, 2002

US-PAT-NO: 6403770

DOCUMENT-IDENTIFIER: US 6403770 B1

TITLE: Antibodies to neutrokin-alpha

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 530/387.3; 435/69.5, 435/7.1, 530/300, 530/324, 530/351, 530/388.1,  
530/388.23

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

HTML	Draw Desc	Image
------	-----------	-------

Generate Collection

Print

Term	Documents
CD40L.DWPI,EPAB,USPT.	251
CD40LS.DWPI,EPAB,USPT.	2
CD40.DWPI,EPAB,USPT.	956
CD40S	0
LIGAND.DWPI,EPAB,USPT.	56962
LIGANDS.DWPI,EPAB,USPT.	40379
GP39.DWPI,EPAB,USPT.	145
GP39S	0
SOLUBLE.DWPI,EPAB,USPT.	447337
SOLUBLES.DWPI,EPAB,USPT.	4183
ITP.DWPI,EPAB,USPT.	670
((CD40L OR CD40 ADJ LIGAND OR GP39)SAME (SOLUBLE) AND (INHIBIT\$ OR SUPPRESS\$ OR BLOCK\$ OR PREVENT\$ OR TREAT\$ OR THERAP\$) SAME (ITP OR THROMBOCYTOPENIA OR PURPURA)).USPT,EPAB,DWPI.	23

[There are more results than shown above. Click here to view the entire set.](#)

**Display Format:**

Change Format

[Previous Page](#)

[Next Page](#)

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\*

Welcome to DIALOG

Dialog level 02.11.01D

Last logoff: 04nov02 09:19:32

Logon file001 06nov02 14:39:42

\*\*\* ANNOUNCEMENT \*\*\*

\*\*\*

--File 515 D&B Dun's Electronic Business Directory is now online completely updated and redesigned. For details, see HELP NEWS 515.

\*\*\*

--File 990 - NewsRoom now contains May 2002 to present records.  
File 993 - NewsRoom archive contains 2002 records from January 2002-April 2002. To search all 2002 records, BEGIN 990,993 or B NEWS2002.

\*\*\*

--Alerts have been enhanced to allow a single Alert profile to be stored and run against multiple files. Duplicate removal is available across files and for up to 12 months. The Alert may be run according to the file's update frequency or according to a custom calendar-based schedule. There are no additional prices for these enhanced features. See HELP ALERT for more information.

\*\*\*

--U.S. Patents Fulltext (File 654) has been redesigned with new search and display features. See HELP NEWS 654 for information.

\*\*\*

--Connect Time joins DialUnits as pricing options on Dialog. See HELP CONNECT for information.

\*\*\*

--CLAIMS/US Patents (Files 340,341, 942) have been enhanced with both application and grant publication level in a single record. See HELP NEWS 340 for information.

\*\*\*

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

\*\*\*

--Important news for public and academic libraries. See HELP LIBRARY for more information.

\*\*\*

--Important Notice to Freelance Authors--  
See HELP FREELANCE for more information

\*\*\*

For information about the access to file 43 please see Help News43.

\*\*\*

NEW FILES RELEASED

\*\*\*Dialog NewsRoom - Current 3-4 months (File 990)

\*\*\*Dialog NewsRoom - 2002 Archive (File 993)

\*\*\*Dialog NewsRoom - 2001 Archive (File 994)

\*\*\*Dialog NewsRoom - 2000 Archive (File 995)

\*\*\*TRADEMARKSCAN-Finland (File 679)

\*\*\*TRADEMARKSCAN-Norway (File 678)

\*\*\*TRADEMARKSCAN-Sweden (File 675)

\*\*\*

UPDATING RESUMED

\*\*\*Delphes European Business (File 481)

\*\*\*

RELOADED

\*\*\*D&B Dun's Electronic Business Directory (File 515)  
\*\*\*U.S. Patents Fulltext 1976-current (File 654)  
\*\*\*Population Demographics (File 581)  
\*\*\*Kompas Western Europe (File 590)  
\*\*\*D&B - Dun's Market Identifiers (File 516)

REMOVED

\*\*\*Chicago Tribune (File 632)  
\*\*\*Fort Lauderdale Sun Sentinel (File 497)  
\*\*\*The Orlando Sentinel (File 705)  
\*\*\*Newport News Daily Press (File 747)  
\*\*\*U.S. Patents Fulltext 1980-1989 (File 653)  
\*\*\*Washington Post (File 146)  
\*\*\*Books in Print (File 470)  
\*\*\*Court Filings (File 793)  
\*\*\*Publishers, Distributors & Wholesalers of the U.S. (File 450)  
\*\*\*State Tax Today (File 791)  
\*\*\*Tax Notes Today (File 790)  
\*\*\*Worldwide Tax Daily (File 792)

\*\*\*New document supplier\*\*\*

IMED has been changed to INFOTRIE (see HELP OINFOTRI)

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<  
>>> of new databases, price changes, etc. <<<  
\*\*\*\*\*

\* \*\*

\*\*\*

File 1:ERIC 1966-2002/Oct 03  
(c) format only 2002 The Dialog Corporation

Set Items Description  
--- -----

Cost is in DialUnits

? b 410

06nov02 14:39:43 User208760 Session D2200.1  
\$0.38 0.109 DialUnits File1  
\$0.38 Estimated cost File1  
\$0.38 Estimated cost this search  
\$0.38 Estimated total session cost 0.109 DialUnits

File 410:Chronolog(R) 1981-2002/Sep  
(c) 2002 The Dialog Corporation

Set Items Description  
--- -----

? set hi ;set hi

HIGHLIGHT set on as ''

HIGHLIGHT set on as ''

? begin 5,73,155,399

06nov02 14:39:57 User208760 Session D2200.2  
\$0.00 0.072 DialUnits File410  
\$0.00 Estimated cost File410  
\$0.05 TELNET  
\$0.05 Estimated cost this search  
\$0.43 Estimated total session cost 0.181 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2002/Oct W4  
(c) 2002 BIOSIS

\*File 5: Alert feature enhanced for multiple files, duplicates  
removal, customized scheduling. See HELP ALERT.

File 73:EMBASE 1974-2002/Oct W4  
(c) 2002 Elsevier Science B.V.  
\*File 73: Alert feature enhanced for multiple files, duplicates  
removal, customized scheduling. See HELP ALERT.  
File 155:MEDLINE(R) 1966-2002/Nov W1  
\*File 155: Alert feature enhanced for multiple files, duplicates  
removal, customized scheduling. See HELP ALERT.  
File 399:CA SEARCH(R) 1967-2002/UD=13719  
(c) 2002 American Chemical Society  
\*File 399: Use is subject to the terms of your user/customer agreement.  
Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set Items Description  
--- ----

? e au=lazarus alan ?

Ref	Items	Index-term
E1	2	AU=LAZARUS A.L.
E2	2	AU=LAZARUS ADAM B
E3	0	*AU=LAZARUS ALAN ?
E4	32	AU=LAZARUS ALAN H
E5	1	AU=LAZARUS AMBER D
E6	3	AU=LAZARUS AMY
E7	1	AU=LAZARUS ANGELINE
E8	7	AU=LAZARUS ANGELINE A
E9	1	AU=LAZARUS ARMAND
E10	9	AU=LAZARUS ARNAUD
E11	6	AU=LAZARUS ARNOLD A
E12	4	AU=LAZARUS ARTHUR

Enter P or PAGE for more

? s e4

S1 32 AU='LAZARUS ALAN H'

? rd s1

...completed examining records

S2 31 RD S1 (unique items)

? s s2 and (cd40L or cd40(W)ligand or gp39)

31 S2

4074 CD40L

16052 CD40

326444 LIGAND

7229 CD40(W)LIGAND

555 GP39

S3 1 S2 AND (CD40L OR CD40(W)LIGAND OR GP39)

? t s3/3/all

3/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

13114985 BIOSIS NO.: 200100322134

Mice lacking CD40 or CD154 (**CD40L**) exhibit distinct abnormalities in  
haemostasis.

AUTHOR: Crow Andrew R(a); Freedman John(a); Mody Meera(a); Rand Margaret L;  
**Lazarus Alan H(a)**

AUTHOR ADDRESS: (a)Transfusion Medicine Research and the Department of  
Laboratory Medicine and Pathobiology, St. Michael's Hospital, Toronto\*\*  
Canada

JOURNAL: Blood 96 (11 Part 1):p622a November 16, 2000

MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of  
Hematology San Francisco, California, USA December 01-05, 2000

SPONSOR: American Society of Hematology

ISSN: 0006-4971



RECORD TYPE: Abstract  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English  
 ? s (cd40L or cd40(W)ligand or gp39) and (itp or thrombocytopenia or purpura)  
     4074 CD40L  
     16052 CD40  
     326444 LIGAND  
     7229 CD40(W)LIGAND  
     555 GP39  
     8065 ITP  
     74619 THROMBOCYTOPENIA  
     35976 PURPURA  
 S4 77 (CD40L OR CD40(W)LIGAND OR GP39) AND (ITP OR  
     THROMBOCYTOPENIA OR PURPURA)  
 ? rd s4  
 ...examined 50 records (50)  
 ...completed examining records  
     S5 54 RD S4 (unique items)  
 ? t s5/3/all

5/3/1 (Item 1 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2002 BIOSIS. All rts. reserv.

13756520 BIOSIS NO.: 200200385341  
 Cardiopulmonary bypass induces release of soluble **CD40 ligand**.  
 AUTHOR: Nannizzi-Alaimo Lisa; Rubenstein Mark H; Alves Veronica L; Leong  
     Gil Y; Phillips David R(a); Gold Herman K  
 AUTHOR ADDRESS: (a)COR Therapeutics, Inc, 256 E Grand Ave, South San  
     Francisco, CA, 94080\*\*USA E-Mail: dphillips@corr.com  
 JOURNAL: Circulation 105 (24):p2849-2854 June 18, 2002  
 MEDIUM: print  
 ISSN: 0009-7322  
 DOCUMENT TYPE: Article  
 RECORD TYPE: Abstract  
 LANGUAGE: English

5/3/2 (Item 2 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2002 BIOSIS. All rts. reserv.

13666633 BIOSIS NO.: 200200295454  
**Thrombocytopenia** in an animal model of malaria is associated with an  
     increased caspase-mediated death of thrombocytes.  
 AUTHOR: Piguet P F(a); Kan C D; Vesin C  
 AUTHOR ADDRESS: (a)Department of Pathology, CMU, 1 Rue M. Servet, 1211,  
     Geneva\*\*Switzerland E-Mail: pierre.piguet@medecine.unige.ch  
 JOURNAL: Apoptosis 7 (2):p91-98 April, 2002  
 MEDIUM: print  
 ISSN: 1360-8185  
 DOCUMENT TYPE: Article  
 RECORD TYPE: Abstract  
 LANGUAGE: English

5/3/3 (Item 3 from file: 5)  
 DIALOG(R)File 5:Biosis Previews(R)  
 (c) 2002 BIOSIS. All rts. reserv.

13613055 BIOSIS NO.: 200200241876  
 Increased soluble and platelet-associated **CD40 ligand** in  
     essential thrombocythemia and reactive thrombocytosis.  
 AUTHOR: Viallard Jean-Francois(a); Solanilla Anne; Gauthier Bruno; Contin

Cecile; Dechanet Julie; Grosset Christophe; Moreau Jean-Francois;  
Praloran Vincent; Nurden Paquita; Pellegrin Jean-Luc; Nurden Alan T;  
Ripoche Jean  
AUTHOR ADDRESS: (a)Dept of Internal Medicine, Hopital Haut-Leveque, 5,  
Avenue Magellan, 33604, Pessac\*\*France E-Mail:  
jean-francois.viallard@chu-bordeaux.fr  
JOURNAL: Blood 99 (7):p2612-2614 April 1, 2002  
MEDIUM: print  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

5/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13581031 BIOSIS NO.: 200200209852  
Immuno-monitoring after a single injection of humanized monoclonal antibody  
to **CD40 ligand** in patients with chronic **ITP**.  
AUTHOR: Kuwana Masataka(a); Nomura Shosaku; Fujimura Kingo; Nagasawa  
Toshiro; Muto Yoshitomo; Kurata Yoshiyuki; Tanaka Shigeru; Ikeda Yasuo(a)  
AUTHOR ADDRESS: (a)Keio University, Tokyo\*\*Japan  
JOURNAL: Blood 98 (11 Part 1):p441a November 16, 2001  
MEDIUM: print  
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of  
Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001  
ISSN: 0006-4971  
RECORD TYPE: Abstract  
LANGUAGE: English

5/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13448679 BIOSIS NO.: 200200077500  
Functional properties of lymphocytes in idiopathic thrombocytopenic  
**purpura**.  
AUTHOR: Webber Nicholas P; Mascarenhas John O; Crow Mary K; Bussel James;  
Schattner Elaine J(a)  
AUTHOR ADDRESS: (a)Division of Hematology-Oncology, Weill Medical College  
of Cornell University, 1300 York Avenue, New York, NY, 10021\*\*USA E-Mail:  
ejsch@med.cornell.edu  
JOURNAL: Human Immunology 62 (12):p1346-1355 December, 2001  
MEDIUM: print  
ISSN: 0198-8859  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

5/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13440343 BIOSIS NO.: 200200069164  
Monocytes from Wiskott-Aldrich patients differentiate in functional mature  
dendritic cells with a defect in CD83 expression.  
AUTHOR: Allavena Paola(a); Badolato Raffaele; Facchetti Fabio; Vermi  
William; Paganin Carla; Luini Walter; Giliani Silvia; Mazza Cinzia;  
Bolzern Ugo; Chiesa Ivana; Notarangelo Luigi; Mantovani Alberto; Sozzani  
Silvano

AUTHOR ADDRESS: (a)Istituto Ricerche Farmacologiche "Mario Negri", Via  
Eritrea 62, 20157, Milan\*\*Italy E-Mail: allavena@marionegri.it  
JOURNAL: European Journal of Immunology 31 (12):p3413-3421 December, 2001  
MEDIUM: print  
ISSN: 0014-2980  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

5/3/7 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13361575 BIOSIS NO.: 200100568724  
Modulation of platelet aggregation in baboons: Implications for mixed  
chimerism in xenotransplantation. I. The roles of individual components  
of a transplantation conditioning regimen and of pig peripheral blood  
progenitor cells.  
AUTHOR: Appel James Z III; Alwayn Ian P J; Buhler Leo; DeAngelis Holly A;  
Robson Simon C; Cooper David K C(a)  
AUTHOR ADDRESS: (a)Transplantation Biology Research Center, Massachusetts  
General Hospital, 13th Street, MGH East, Building 149-9019, Boston, MA,  
01129: David.Cooper@tbrb.mgh.harvard.edu\*\*USA  
JOURNAL: Transplantation (Baltimore) 72 (7):p1299-1305 October 15, 2001  
MEDIUM: print  
ISSN: 0041-1337  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/8 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13211666 BIOSIS NO.: 200100418815  
Role of CD40-**CD40L** in mouse severe malaria.  
AUTHOR: Piguet Pierre Francois(a); Da Kan Chen; Vesin Christian; Rochat  
Anne; Donati Yves; Barazzone Constance  
AUTHOR ADDRESS: (a)Department of Pathology, CMU, 1 Rue M. Servet, 1211,  
Geneva: pierre.piguet@medecine.unige.ch\*\*Switzerland  
JOURNAL: American Journal of Pathology 159 (2):p733-742 August, 2001  
MEDIUM: print  
ISSN: 0002-9440  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/9 (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13183747 BIOSIS NO.: 200100390896  
Porcine hematopoietic cell xenotransplantation in nonhuman primates is  
complicated by thrombotic microangiopathy.  
AUTHOR: Buhler L; Goepfert C; Kitamura H; Basker M; Gojo S; Alwayn I P J;  
Chang Q; Down J D; Tsai H; Wise R; Sachs D H; Cooper D K C; Robson S C;  
Sackstein R(a)  
AUTHOR ADDRESS: (a)Harvard Institutes of Medicine, 77 Avenue Louis Pasteur,  
Room 671, Boston, MA, 02115\*\*USA

JOURNAL: Bone Marrow Transplantation 27 (12):p1227-1236 June 2, 2001  
MEDIUM: print  
ISSN: 0268-3369  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/10 (Item 10 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13161856 BIOSIS NO.: 200100369005  
Elevated plasma levels of inflammatory markers in heparin-induced  
**thrombocytopenia**: Pathophysiologic implications.  
AUTHOR: Hoppensteadt D A(a); Ahmad S(a); Walenga J M(a); Jeske W P(a); Bano  
A(a); Demir M(a); Mousa S A; Bakhos M(a); Fareed J(a)  
AUTHOR ADDRESS: (a)Loyola University Chicago, Maywood, IL\*\*USA  
JOURNAL: Clinical Chemistry 47 (S6):pA161 June, 2001  
MEDIUM: print  
CONFERENCE/MEETING: 53rd Annual Meeting of the AACCC/SCC Chicago,  
Illinois, USA July 29-August 02, 2001  
ISSN: 0009-9147  
RECORD TYPE: Citation  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/11 (Item 11 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13110067 BIOSIS NO.: 200100317216  
CD154 (**CD40-ligand**) gene therapy for chronic lymphocytic  
leukemia: Follow-up of a Phase I study.  
AUTHOR: Wierda W G(a); Rassenti L Z(a); Cantwell M J; Woods S J(a); Kipps T  
J(a)  
AUTHOR ADDRESS: (a)Division of Heme/Onc and Human Gene Therapy Program,  
UCSD School of Medicine, La Jolla, CA\*\*USA  
JOURNAL: Blood 96 (11 Part 1):p800a November 16, 2000  
MEDIUM: print  
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of  
Hematology San Francisco, California, USA December 01-05, 2000  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/12 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13098436 BIOSIS NO.: 200100305585  
The role of **CD40 ligand** and anti-annexin V antibodies in the  
pathophysiology of APS and HIT.  
AUTHOR: Baugh Matthew J(a); Prechel Margaret(a); Hoppensteadt Debra(a);  
Wallis Elizabeth(a); Bick Rodger L; Walenga Jeanine M(a)  
AUTHOR ADDRESS: (a)Cardiovascular Institute, Loyola University Chicago,  
Maywood, IL\*\*USA  
JOURNAL: Blood 96 (11 Part 1):p272a November 16, 2000  
MEDIUM: print

CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/13 (Item 13 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13098158 BIOSIS NO.: 200100305307  
Elevated plasma levels of inflammatory markers in heparin-induced **thrombocytopenia**.  
AUTHOR: Fareed J(a); Ahmad S(a); Walenga J M(a); Hoppensteadt D A(a); Jeske W P(a); Demir M(a); Mousa S A; Bakhos M(a)  
AUTHOR ADDRESS: (a)Pathology and Thoracic and Cardiovascular Surgery, Loyola Univ. Chicago, Maywood, IL\*\*USA  
JOURNAL: Blood 96 (11 Part 2):p94b November 16, 2000  
MEDIUM: print  
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/14 (Item 14 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13098078 BIOSIS NO.: 200100305227  
Upregulation of immunoglobulins may be associated with the pathogenesis of heparin-induced **thrombocytopenia**.  
AUTHOR: Fareed J(a); Ahmad S(a); Walenga J M(a); Aldabbagh A(a); Jeske W P(a); Demir M(a); Bakhos M(a)  
AUTHOR ADDRESS: (a)Pathology and Thoracic and Cardiovascular Surgery, Loyola Univ. Chicago, Maywood, IL\*\*USA  
JOURNAL: Blood 96 (11 Part 2):p64b-65b November 16, 2000  
MEDIUM: print  
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000  
SPONSOR: American Society of Hematology  
ISSN: 0006-4971  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/15 (Item 15 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12948319 BIOSIS NO.: 200100155468  
Lymphocytes apoptosis and the related factors of Henoch Schonlein's **purpura** in acute phase.  
AUTHOR: Li Qiu(a); Yang Xiqiang; Liu Enmei; et al  
AUTHOR ADDRESS: (a)Children's Hospital, Chongqing University of Medical Science, Chongqing, 400014: Diannong@public.cta.cq.ch\*\*China  
JOURNAL: Zhonghua Weishengwuxue He Mianyixue Zazhi 20 (5):p411-413

September, 2000  
MEDIUM: print  
ISSN: 0254-5101  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: Chinese; Non-English  
SUMMARY LANGUAGE: Chinese; English

5/3/16 (Item 16 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12834847 BIOSIS NO.: 200100041996  
Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome.  
AUTHOR: Minegishi Yoshiyuki(a); Lavoie Aubert; Cunningham-Rundles Charlotte; Bedard Pierre-Michel; Hebert Jacques; Cote Louise; Dan Kazuo; Sedlak Debra; Buckley Rebecca H; Fischer Alain; Durandy Anne; Conley Mary Ellen (a)  
AUTHOR ADDRESS: (a)Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, 38101-0318\*\*USA  
JOURNAL: Clinical Immunology (Orlando) 97 (3):p203-210 December, 2000  
MEDIUM: print  
ISSN: 1521-6616  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/17 (Item 17 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12785494 BIOSIS NO.: 200000539117  
**CD40-ligand** (CD154) gene therapy for chronic lymphocytic leukemia.  
AUTHOR: Wierda William G; Cantwell Mark J; Woods Sandra J; Rassenti Laura Z; Prussak Charles E; Kipps Thomas J(a)  
AUTHOR ADDRESS: (a)Division of Hematology and Oncology, Department of Medicine, University of California-San Diego, 9500 Gilman Dr, La Jolla, CA, 92093-0663\*\*USA  
JOURNAL: Blood 96 (9):p2917-2924 November 1, 2000  
MEDIUM: print  
ISSN: 0006-4971  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/18 (Item 18 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12662210 BIOSIS NO.: 200000415712  
Von Willebrand factor concentration, multimeric patterns, and cleaving protease activity in baboons undergoing xenogeneic peripheral blood stem cell transplantation.  
AUTHOR: Gopfert C(a); Buhler L; Wise R; Basker M; Gojo S; Imai M; Alwayn I; Sachs D H; Sackstein R; Cooper D K C; Robson S C  
AUTHOR ADDRESS: (a)Immunobiology Research Center, Harvard Medical School, 99 Brookline Ave, Boston, MA, 02215\*\*USA

JOURNAL: Transplantation Proceedings 32 (5):p990 August, 2000  
MEDIUM: print  
CONFERENCE/MEETING: 5th Congress of the International Xenotransplantation Association Nagoya, Japan October 24-28, 1999  
SPONSOR: Transplantation Society  
ISSN: 0041-1345  
RECORD TYPE: Citation  
LANGUAGE: English  
SUMMARY LANGUAGE: English

5/3/19 (Item 19 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12287182 BIOSIS NO.: 200000045049  
Safety and effect on platelet count of repeated doses of monoclonal antibody to **CD40 ligand** in patients with chronic **ITP**.  
AUTHOR: George J; Raskob G; Bussel J; Cobos E; Green D; Tongol J; Rutherford C; Wasser J; Croft H; Rhinehart S; Oates B; Scaramucci J; Nadeau K  
JOURNAL: Blood 94 (10 SUPPL. 1 PART 1):p19a Nov. 15, 1999  
CONFERENCE/MEETING: Forty-first Annual Meeting of the American Society of Hematology New Orleans, Louisiana, USA December 3-7, 1999  
SPONSOR: The American Society of Hematology  
ISSN: 0006-4971  
RECORD TYPE: Citation  
LANGUAGE: English

5/3/20 (Item 20 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12285819 BIOSIS NO.: 200000043686  
Humanized monoclonal anti-**CD40 ligand** antibody (hu5c8) rescue therapy of 15 adults with severe chronic refractory **ITP**.  
AUTHOR: Bussel James(a); Wissert Megan(a); Oates Barry; Scaramucci James; Nadeau Kari; Adelman Burt  
AUTHOR ADDRESS: (a)Pediatric Hematology/Oncology, Weill-Cornell Med., New York, NY\*\*USA  
JOURNAL: Blood 94 (10 SUPPL. 1 PART 1):p646a Nov. 15, 1999  
CONFERENCE/MEETING: Forty-first Annual Meeting of the American Society of Hematology New Orleans, Louisiana, USA December 3-7, 1999  
SPONSOR: The American Society of Hematology  
ISSN: 0006-4971  
RECORD TYPE: Citation  
LANGUAGE: English

5/3/21 (Item 21 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

11892344 BIOSIS NO.: 199900138453  
Clinical and immunologic spectrum of the hyper IgM syndrome.  
AUTHOR: Uthaisangsook S; Buckley R H  
AUTHOR ADDRESS: Duke Univ. Med. Cent., Durham, NC\*\*USA  
JOURNAL: Journal of Allergy and Clinical Immunology 103 (1 PART 2):p S148-S149 Jan., 1999  
CONFERENCE/MEETING: 55th Annual Meeting of the American Academy of Allergy, Asthma and Immunology Orlando, Florida, USA February 26-March 3, 1999  
SPONSOR: American Academy of Allergy, Asthma, and Immunology  
ISSN: 0091-6749

RECORD TYPE: Citation  
LANGUAGE: English

5/3/22 (Item 22 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

11876441 BIOSIS NO.: 199900122550  
A thrombotic disorder complicating xenogenic peripheral blood stem cell  
transplantation: A primate model of thrombotic thrombocytopenic  
**purpura** (TTP).  
AUTHOR: Buhler L(a); Goepfert C; Basker M; Gojo S; Guckelberger O; Nash K;  
Chang Q; Watts A; Treter S; Awwad M; Shimizu A; Andrews D; White-Scharf M  
; Sachs D H; Robson S C; Cooper D K C; Sackstein R  
AUTHOR ADDRESS: (a)Transplantation Biology Res. Cent., Mass. General Hosp.,  
Boston, MA\*\*USA  
JOURNAL: Blood 92 (10 SUPPL. 1 PART 1-2):p706A Nov. 15, 1998  
CONFERENCE/MEETING: 40th Annual Meeting of the American Society of  
Hematology Miami Beach, Florida, USA December 4-8, 1998  
SPONSOR: The American Society of Heamatology  
ISSN: 0006-4971  
RECORD TYPE: Citation  
LANGUAGE: English

5/3/23 (Item 23 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

11873973 BIOSIS NO.: 199900120082  
Safety and effect on platelet count of single-dose monoclonal antibody to  
**CD40 ligand** (ANTOVA) in patients with chronic **ITP**.  
AUTHOR: George J; Raskob G; Lichtin A; Bussel J; Cobos E; Green D; Malone R  
; Rutherford C; Wasser J; Tenhoor C; Nadeau K  
AUTHOR ADDRESS: Univ. Okla., Oklahoma City, OK\*\*USA  
JOURNAL: Blood 92 (10 SUPPL. 1 PART 1-2):p707A Nov. 15, 1998  
CONFERENCE/MEETING: 40th Annual Meeting of the American Society of  
Hematology Miami Beach, Florida, USA December 4-8, 1998  
SPONSOR: The American Society of Heamatology  
ISSN: 0006-4971  
RECORD TYPE: Citation  
LANGUAGE: English

5/3/24 (Item 24 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

11857438 BIOSIS NO.: 199900103547  
Platelet **CD40L** (**CD40 ligand**) is a manor target antigen in  
immune mediated **thrombocytopenia**.  
AUTHOR: Nugent D; Nakagawa P  
AUTHOR ADDRESS: Child. Hosp. Orange County, Orange, CA\*\*USA  
JOURNAL: Blood 92 (10 SUPPL. 1 PART 1-2):p176A Nov. 15, 1998  
CONFERENCE/MEETING: 40th Annual Meeting of the American Society of  
Hematology Miami Beach, Florida, USA December 4-8, 1998  
SPONSOR: The American Society of Heamatology  
ISSN: 0006-4971  
RECORD TYPE: Citation  
LANGUAGE: English

5/3/25 (Item 25 from file: 5)



DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

11537540 BIOSIS NO.: 199800318872  
Molecular characteristics of the gene **CD40L** in hypogammaglobulinemia  
with hyperproduction of immunoglobulin M (hyper-IgM-syndrome).  
AUTHOR: Reznik I B(a); Notarangelo L; Villa A; Giliani S; Kondratenko I V;  
Kovalev G I; Aref'eva T; Gomes L A; Bologov A A; Reznikov Yu P  
AUTHOR ADDRESS: (a)Dep. Clin. Immunol., Res. Inst. Pediatr. Hematol.,  
Minist. Health Russ. Fed., Moscow\*\*Russia  
JOURNAL: Immunologiya 0 (2):p22-26 March-April, 1998  
ISSN: 0206-4952  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: Russian; Non-English  
SUMMARY LANGUAGE: English

5/3/26 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11761921 EMBASE No: 2002334787  
Novel therapeutics for the treatment of graft-versus-host disease  
Jacobsohn D.A.  
Dr. D.A. Jacobsohn, Department of Haematology/Oncology, Children's  
Memorial Hospital, Northwestern University, 2300 Children's Plaza,  
Chicago, IL 60614 United States  
Expert Opinion on Investigational Drugs ( EXPERT OPIN. INVEST. DRUGS ) (  
United Kingdom) 2002, 11/9 (1271-1280)  
CODEN: EOIDE ISSN: 1354-3784  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 81

5/3/27 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11597255 EMBASE No: 2002169641  
Treatment options for juvenile-onset systemic lupus erythematosus  
Carren(tilde)o L.; Lopez-Longo F.J.; Gonzalez C.M.; Monteagudo I.  
Dr. L. Carren(tilde)o, Servicio de Reumatologia, Hosp. Gen. Univ.,  
Gregorio Maranon, Dr Esquerdo 46, Madrid 28007 Spain  
AUTHOR EMAIL: reuma@ipmq.hggm.es  
Paediatric Drugs ( PAEDIATR. DRUGS ) (New Zealand) 2002, 4/4 (241-256)  
CODEN: PTDGF ISSN: 1174-5878  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 134

5/3/28 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11564292 EMBASE No: 2002134097  
Novel approaches to refractory immune thrombocytopenic **purpura**  
Bussel J.B.  
Dr. J.B. Bussel, Department of Pediatrics, Weill Med. Coll. of Cornell  
Univ., 525 East 68th Street, New York, NY 10021 United States  
AUTHOR EMAIL: jbusssel@med.cornell.edu  
Blood Reviews ( BLOOD REV. ) (United Kingdom) 2002, 16/1 (31-36)

CODEN: BLORE ISSN: 0268-960X  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 57

5/3/29 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11545864 EMBASE No: 2002112715  
Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic **purpura**  
Kuwana M.; Okazaki Y.; Kaburaki J.; Kawakami Y.; Ikeda Y.  
Dr. M. Kuwana, Inst. for Advanced Medical Research, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan  
AUTHOR EMAIL: kuwanam@sc.itc.keio.ac.jp  
Journal of Immunology ( J. IMMUNOL. ) (United States) 01 APR 2002, 168/7 (3675-3682)  
CODEN: JOIMA ISSN: 0022-1767  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 33

5/3/30 (Item 5 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11453260 EMBASE No: 2002024119  
Induction therapy in renal transplantation  
Shidban H.  
Dr. H. Shidban, 2200 West Third Street, Los Angeles, CA 90057 United States  
AUTHOR EMAIL: hamidshidbanMD@aol.com  
Current Opinion in Organ Transplantation ( CURR. OPIN. ORGAN TRANSPLANT. ) (United States) 2001, 6/4 (320-326)  
CODEN: COOTA ISSN: 1087-2418  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 39

5/3/31 (Item 6 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11371614 EMBASE No: 2001387542  
Modulation of platelet aggregation in baboons: Implications for mixed chimerism in xenotransplantation. I. The roles of individual components of a transplantation conditioning regimen and of pig peripheral blood progenitor cells  
Appel III J.Z.; Alwayn I.P.J.; Buhler L.; DeAngelis H.A.; Robson S.C.; Cooper D.K.C.  
Dr. D.K.C. Cooper, Transplantation Biol. Res. Center, Massachusetts General Hospital, MGH East, 13th Street, Boston, MA 01129 United States  
AUTHOR EMAIL: David.Cooper@tbrc.mgh.harvard.edu  
Transplantation ( TRANSPLANTATION ) (United States) 15 OCT 2001, 72/7 (1299-1305)  
CODEN: TRPLA ISSN: 0041-1337  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 41

5/3/32 (Item 7 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11230130 EMBASE No: 2001245030  
New developments in the prophylaxis and treatment of graft versus host disease  
Simpson D.  
D. Simpson, North Shore Hospital, Private Bag 93-503, Auckland 9 New Zealand  
AUTHOR EMAIL: david.simpson@whl.co.nz  
Expert Opinion on Pharmacotherapy ( EXPERT OPIN. PHARMACOTHER. ) (United Kingdom) 2001, 2/7 (1109-1117)  
CODEN: EOPHF ISSN: 1465-6566  
DOCUMENT TYPE: Journal ; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 68

5/3/33 (Item 8 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11040677 EMBASE No: 2001073341  
Overview of idiopathic thrombocytopenic **purpura**: New approach to refractory patients  
Bussel J.B.  
Dr. J.B. Bussel, Weill Med. College of Cornell Univ., Department of Pediatrics, Div. of Pediatric Hematol./Oncology, 525 E 68th St, New York, NY 10021 United States  
Seminars in Oncology ( SEMIN. ONCOL. ) (United States) 2000, 27/6  
SUPPL. 12 (91-98)  
CODEN: SOLGA ISSN: 0093-7754  
DOCUMENT TYPE: Journal ; Conference Paper  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 25

5/3/34 (Item 9 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

10755680 EMBASE No: 2000236486  
Therapy of systemic lupus erythematosus: New agents and new evidence  
Ruiz-Irastorza G.; Khamashta M.A.; Hughes G.R.V.  
M.A. Khamashta, Lupus Research unit, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH United Kingdom  
AUTHOR EMAIL: 106404.2325@Compuserve.com  
Expert Opinion on Investigational Drugs ( EXPERT OPIN. INVEST. DRUGS ) (United Kingdom) 2000, 9/7 (1581-1593)  
CODEN: EOIDE ISSN: 1354-3784  
DOCUMENT TYPE: Journal; Review  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 72

5/3/35 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)

13609102 22207208 PMID: 12218076  
Role of the tumor necrosis factor receptor 2 (TNFR2) in cerebral malaria in mice.  
Piguet Pierre Francois; Kan Chen Da; Vesin Christian

Department of Pathology, Universite de Geneve, Geneva, Switzerland.  
perre.piguet@medecine.unige.ch

Laboratory investigation; a journal of technical methods and pathology (United States) Sep 2002, 82 (9) p1155-66, ISSN 0023-6837  
Journal Code: 0376617

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

5/3/36 (Item 2 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

13588022 21959512 PMID: 11960513

Treatment options for juvenile-onset systemic lupus erythematosus.

Carreno Luis; Lopez-Longo Francisco Javier; Gonzalez Carlos Manuel; Monteagudo Indalecio

Service of Rheumatology, General University Hospital Gregorio Mara, Complutense University of Madrid, Madrid, Spain. reuma@ipmq.hggm.es

Paediatric drugs (New Zealand) 2002, 4 (4) p241-56, ISSN 1174-5878  
Journal Code: 100883685

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

5/3/37 (Item 3 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

13318081 22084912 PMID: 12090546

IDEC-131. IDEC/Eisai.

Dumont Francis J

Merck Research Laboratories, Department of Immunology, Rahway, NJ 07065, USA. francis.dumont@merck.com

Current opinion in investigational drugs (London, England : 2000) (England) May 2002, 3 (5) p725-34, ISSN 1472-4472 Journal Code: 100965718

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

5/3/38 (Item 4 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

13020516 21903029 PMID: 11904968

[Monoclonal antibody therapy for disorders of hemostasis and coagulation]

Nishimura Susumu; Ishida Tadao; Imai Kohzoh

First Department of Internal Medicine, Sapporo Medical University.

Nippon rinsho. Japanese journal of clinical medicine (Japan) Mar 2002, 60 (3) p525-30, ISSN 0047-1852 Journal Code: 0420546

Document type: Journal Article; Review; Review, Tutorial ; English Abstract

Languages: JAPANESE

Main Citation Owner: NLM

Record type: Completed

5/3/39 (Item 5 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

12918637 21656627 PMID: 11797399

Determination of activated platelets: evaluation of methodology and application for patients with idiopathic thrombocytopenic **purpura**

Hayashi S; Oshida M; Kiyokawa T; Aochi H; Honda S; Tomiyama Y; Kurata Y  
Department of Blood Transfusion, Osaka University Hospital, Suita  
565-0871.

Rinsho byori. The Japanese journal of clinical pathology (Japan) Dec  
2001, 49 (12) p1287-92, ISSN 0047-1860 Journal Code: 2984781R

Document type: Journal Article ; English Abstract

Languages: JAPANESE

Main Citation Owner: NLM

Record type: Completed

5/3/40 (Item 6 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

11326780 21378029 PMID: 11485931

Role of CD40-CVD40L in mouse severe malaria.

Piguet P F; Kan C D; Vesin C; Rochat A; Donati Y; Barazzone C

Department of Pathology, University of Geneva, 1 rue M. Servet, CMU, 1211  
Geneva, Switzerland. pierre.piguet@medecine.unige.ch

American journal of pathology (United States) Aug 2001, 159 (2)  
p733-42, ISSN 0002-9440 Journal Code: 0370502

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

5/3/41 (Item 7 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

10820494 20350107 PMID: 10892186

New development in the treatment of idiopathic thrombocytopenic  
**purpura**

Kurata Y

Zasshi Journal. Nihon Naika Gakkai (JAPAN) Jun 10 2000, 89 (6)  
p1114-20, ISSN 0021-5384 Journal Code: 19130210R

Document type: Journal Article; Review; Review, Tutorial

Languages: JAPANESE

Main Citation Owner: NLM

Record type: Completed

5/3/42 (Item 8 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

09857952 98309480 PMID: 9647265

Immunodeficiency with elevated IgM, lymphoid hyperplasia, autoimmune  
anemia, and **thrombocytopenia**.

Hilman B C; Wahid R; Negrich R; Menon P; Abreo F; Veillon D

Department of Pediatrics, Louisiana State University Medical Center,  
Shreveport 71130-3932, USA.

Annals of allergy, asthma & immunology : official publication of the  
American College of Allergy, Asthma, & Immunology (UNITED STATES) Jun  
1998, 80 (6) p441-51, ISSN 1081-1206 Journal Code: 9503580

Document type: Clinical Conference; Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

5/3/43 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

137200261 CA: 137(14)200261v PATENT  
Humanized anti-human gp39 antibodies for treating autoimmune diseases  
INVENTOR(AUTHOR): Black, Amelia; Hanna, Nabil; Padlan, Eduardo A.;  
Newman, Roland A.  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals Corporation  
PATENT: United States ; US 6440418 B1 DATE: 20020827  
APPLICATION: US 925339 (19970908) \*US 554840 (19951107)  
PAGES: 50 pp., Cont.-in-part of U. S. 6,001,358. CODEN: USXXAM  
LANGUAGE: English CLASS: 424154100; A61K-039/395A; C07K-016/28B

5/3/44 (Item 2 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

136246408 CA: 136(16)246408f PATENT  
Combination therapy for treatment of autoimmune diseases using B cell  
depleting/immunoregulatory antibody combination.  
INVENTOR(AUTHOR): Hanna, Nabil  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals  
PATENT: PCT International ; WO 200222212 A2 DATE: 20020321  
APPLICATION: WO 2001US29026 (20010918) \*US PV257147 (20001222)  
PAGES: 58 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61P-037/00;  
A61K-039/39 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
BR; BY; CA; CH; CN; CO; CU; CZ; EE; ES; FI; GB; GE; GM; HU; ID; IL; IN; KP;  
KR; LK; LR; MN; MW; MX; NO; NZ; PL; PT; RO; RU DESIGNATED REGIONAL: GH; GM  
; KE; LS; MW; MZ; SD; SL; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR;  
GB; GR; IE; IT; MC; NL; PT; SE; TR; CG; CI; GA; GN; GW; ML; MR; NE; SN; TD;  
TG

5/3/45 (Item 3 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

136052724 CA: 136(4)52724k PATENT  
Methods for regulating a cell-mediated immune response by blocking  
lymphocytic signals and by blocking LFA-1 mediated adhesion  
INVENTOR(AUTHOR): Townsend, Robert M.; Todderud, Charles Gordon; Peach,  
Robert J.  
LOCATION: USA  
ASSIGNEE: Bristol-Myers Squibb Company  
PATENT: PCT International ; WO 200195928 A2 DATE: 20011220  
APPLICATION: WO 2001US18619 (20010608) \*US PV210671 (20000609)  
PAGES: 75 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/17A;  
A61K-039/395B; A61P-037/00B; C07K-014/705B; C07K-016/28B; A61K-039/395B;  
A61K-038/17B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB;  
GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR;  
LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD;  
SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM;  
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ  
; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE;  
IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE;  
SN; TD; TG

5/3/46 (Item 4 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 American Chemical Society. All rts. reserv.

136036363 CA: 136(3)36363m PATENT  
Non-agonistic antibodies to human gp39, compositions containing, and  
therapeutic use thereof  
INVENTOR(AUTHOR): Anderson, Darrell R.; Pan, Li Zhen; Hanna, Nabil;  
Rastetter, William H.; Kloetzer, William S.  
LOCATION: USA  
ASSIGNEE: Idec Pharmaceuticals Corporation  
PATENT: PCT International ; WO 200194586 A2 DATE: 20011213  
APPLICATION: WO 2001US18098 (20010606) \*US PV209584 (20000606)  
PAGES: 130 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/13A;  
C07K-016/28B; A61K-039/395B; A61P-037/06B; A61K-048/00B; C12N-015/63B;  
C12N-015/86B; C12N-015/861B; C12N-015/867B; C12N-015/11B

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;  
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI;  
SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ;  
MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ  
; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;  
PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

5/3/47 (Item 5 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 American Chemical Society. All rts. reserv.

134236228 CA: 134(17)236228s PATENT  
CD40 ligand and CD40 agonist compositions and methods of use  
INVENTOR(AUTHOR): Ahuja, Seema S.; Bonewald, Lynda F.  
LOCATION: USA  
ASSIGNEE: Board of Regents, the University of Texas System  
PATENT: PCT International ; WO 200116180 A2 DATE: 20010308  
APPLICATION: WO 2000US23276 (20000824) \*US PV151250 (19990827)  
PAGES: 117 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/705A;  
C07K-016/28B; A61K-038/17B; A61K-039/395B; A61P-019/10B  
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;  
CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR;  
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;  
MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;  
TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;  
TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW  
; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE;  
BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

5/3/48 (Item 6 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 American Chemical Society. All rts. reserv.

134021432 CA: 134(2)21432t PATENT  
Preventives for idiopathic thrombocytopenic purpura  
INVENTOR(AUTHOR): Yamauchi, Toshihiko; Yokohama, Hiromitsu; Kobayashi,  
Seiichi; Seto, Toshio  
LOCATION: Japan,  
ASSIGNEE: Eisai Co., Ltd.  
PATENT: PCT International ; WO 200072882 A1 DATE: 20001207  
APPLICATION: WO 2000JP3478 (20000530) \*JP 99153383 (19990601)  
PAGES: 17 pp. CODEN: PIXXD2 LANGUAGE: Japanese CLASS: A61K-045/00A;  
A61K-039/395B; A61P-007/04B DESIGNATED COUNTRIES: JP; US  
DESIGNATED REGIONAL: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;  
LU; MC; NL; PT; SE

5/3/49 (Item 7 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

133037640 CA: 133(4)37640z JOURNAL  
Developments in treatment of idiopathic thrombocytopenic purpura  
AUTHOR(S): Kurata, Yoshiyuki  
LOCATION: Dep. of Blood Transfus., Osaka Univ., Japan,  
JOURNAL: Nippon Naika Gakkai Zasshi DATE: 2000 VOLUME: 89 NUMBER: 6  
PAGES: 1114-1120 CODEN: NNGAAS ISSN: 0021-5384 LANGUAGE: Japanese  
PUBLISHER: Nippon Naika Gakkai

5/3/50 (Item 8 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

131031035 CA: 131(3)31035t PATENT  
Use of a soluble recombinant human CD40L protein for inhibiting in vivo  
immune response  
INVENTOR(AUTHOR): Lazarus, Alan H.; Crow, Andrew R.; Freedman, John  
LOCATION: Can.,  
ASSIGNEE: Canadian Blood Services  
PATENT: PCT International ; WO 9927948 A2 DATE: 19990610  
APPLICATION: WO 98CA1105 (19981127) \*CA 2223225 (19971128)  
PAGES: 42 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/17A;  
G01N-033/48B; A01K-067/027B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA;  
BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; HR;  
HU; ID; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG;  
MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR;  
TT; UA; UG; US; UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM  
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY;  
DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;  
CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

5/3/51 (Item 9 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

130094477 CA: 130(8)94477p PATENT  
CD154 blockade therapy for autoimmune diseases  
INVENTOR(AUTHOR): Thomas, David W.  
LOCATION: USA  
ASSIGNEE: Biogen, Inc.  
PATENT: PCT International ; WO 9900143 A1 DATE: 19990107  
APPLICATION: WO 98US13284 (19980626) \*US 51072 (19970627) \*US 51481  
(19970701) \*US 51483 (19970701) \*US 51484 (19970701)  
PAGES: 33 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A  
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;  
CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG;  
KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;  
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; US; US; US;  
UZ; VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH  
; GM; KE; LS; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE;  
SN; TD; TG

5/3/52 (Item 10 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.



129229685 CA: 129(18)229685g PATENT  
Methods of therapeutic administration of anti-CD40L monoclonal antibody  
INVENTOR(AUTHOR): Kalled, Susan L.; Thomas, David W.  
LOCATION: USA  
ASSIGNEE: Biogen, Inc.  
PATENT: PCT International ; WO 9839026 A2 DATE: 19980911  
APPLICATION: WO 97US24133 (19971231) \*US 40154 (19970307)  
PAGES: 31 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/00A  
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;  
CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG;  
KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;  
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS  
; MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;  
MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

5/3/53 (Item 11 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

129104214 CA: 129(9)104214w PATENT  
Methods of therapeutic administration of anti-CD40L compounds for  
treating antibody-related disease  
INVENTOR(AUTHOR): Kalled, Susan L.; Thomas, David W.  
LOCATION: USA  
ASSIGNEE: Biogen, Inc.; Kalled, Susan L.; Thomas, David W.  
PATENT: PCT International ; WO 9830241 A1 DATE: 19980716  
APPLICATION: WO 98US573 (19980109) \*US 34672 (19970110) \*US 40154  
(19970307)  
PAGES: 36 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A  
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;  
CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; GW; HU; ID; IL; IS; JP; KE; KG;  
KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;  
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS  
; MW; SD; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;  
MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

5/3/54 (Item 12 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

127175393 CA: 127(13)175393y PATENT  
Therapeutic applications of T-BAM (CD40L) technology to treat  
inflammatory kidney diseases  
INVENTOR(AUTHOR): Yellin, Michael J.; Lederman, Seth; Chess, Leonard;  
Karpusas, Mihail N.; Thomas, David W.  
LOCATION: USA  
ASSIGNEE: Trustees of Columbia Univeristy in the City of New York;  
Biogen, Inc.  
PATENT: PCT International ; WO 9726000 A1 DATE: 19970724  
APPLICATION: WO 97US668 (19970116) \*US 587334 (19960116) \*US 641473  
(19960501)  
PAGES: 83 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/02A;  
A61K-038/17B; A61K-039/395B DESIGNATED COUNTRIES: AU; CA; JP; MX  
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU;  
MC; NL; PT; SE  
?

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 20 of 23 returned.**☐ 11. Document ID: US 6391589 B1

L6: Entry 11 of 23

File: USPT

May 21, 2002

US-PAT-NO: 6391589

DOCUMENT-IDENTIFIER: US 6391589 B1

TITLE: Human chemokine beta-10 mutant polypeptides

DATE-ISSUED: May 21, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olsen; Henrik S.	Gaithersburg	MD		
Li; Haodong	Gaithersburg	MD		
Adams; Mark D.	North Potomac	MD		
Gentz; Solange H. L.	Rockville	MD		
Alderson; Ralph	Gaithersburg	MD		
Li; Yuling	Germantown	MD		
Parmelee; David	Rockville	MD		
White; John R.	Coatsville	PA		
Appelbaum; Edward R.	Blue Bell	PA		

US-CL-CURRENT: 435/69.5; 424/85.1, 435/252.3, 435/254.11, 435/320.1, 435/325,  
435/471, 435/71.1, 435/71.2, 514/12, 514/2 , 514/8, 530/324, 536/23.1, 536/23.5[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[RIMC](#) [Draw Desc](#) [Image](#)☐ 12. Document ID: US 6372473 B1

L6: Entry 12 of 23

File: USPT

Apr 16, 2002

US-PAT-NO: 6372473

DOCUMENT-IDENTIFIER: US 6372473 B1

TITLE: Tissue plasminogen activator-like protease

DATE-ISSUED: April 16, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		
Ebner; Reinhard	Gaithersburg	MD		

US-CL-CURRENT: 435/212; 435/217, 530/327, 530/328, 530/350, 530/827, 530/828[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#)[RIMC](#) [Draw Desc](#) [Image](#)

☐ 13. Document ID: US 6358508 B1

L6: Entry 13 of 23

File: USPT

Mar 19, 2002

US-PAT-NO: 6358508

DOCUMENT-IDENTIFIER: US 6358508 B1

TITLE: Antibodies to human tumor necrosis factor receptor TR9

DATE-ISSUED: March 19, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Rockville	MD		
Yu; Guo-Liang	Berkeley	CA		
Fan; Ping	Gaithersburg	MD		
Gentz; Reiner L.	Rockville	MD		

US-CL-CURRENT: 424/139.1; 424/178.1, 530/387.9, 530/388.22, 530/389.1, 530/391.3, 530/391.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

Keyword	Draw Desc	Image
---------	-----------	-------

☒ 14. Document ID: US 6315998 B1

L6: Entry 14 of 23

File: USPT

Nov 13, 2001

US-PAT-NO: 6315998

DOCUMENT-IDENTIFIER: US 6315998 B1

TITLE: Methods of blocking B-cell activation using anti-CD40 monoclonal antibodies

DATE-ISSUED: November 13, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Boer; Mark	Beuerwijk			NL
Conroy; Leah B.	Pacifica	CA		

US-CL-CURRENT: 424/144.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/153.1, 424/173.1, 530/387.1, 530/387.3, 530/388.1, 530/388.2, 530/388.22, 530/388.7, 530/388.73

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

Keyword	Draw Desc	Image
---------	-----------	-------

☐ 15. Document ID: US 6291645 B1

L6: Entry 15 of 23

File: USPT

Sep 18, 2001

US-PAT-NO: 6291645

DOCUMENT-IDENTIFIER: US 6291645 B1

TITLE: p62 polypeptides, related polypeptides, and uses therefor

DATE-ISSUED: September 18, 2001

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shin; Jaekyoon	Westwood	MA		
Joung; Insil	Boston	MA		
Vadlamudi; Ratna K.	Norwood	MA		
Strominger; Jack L.	Lexington	MA		

US-CL-CURRENT: 530/350

Full	Title	Classification	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------------	-------	--------	----------------	------	-----------	-----------	-------------

Title	Draw Desc	Image
-------	-----------	-------

☐ 16. Document ID: US 6056959 A

L6: Entry 16 of 23

File: USPT

May 2, 2000

US-PAT-NO: 6056959

DOCUMENT-IDENTIFIER: US 6056959 A

TITLE: CD40 antigen antibody complex

DATE-ISSUED: May 2, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Boer; Mark	Beverwyk			NL
Conroy; Leah B	Pacifica	CA		

US-CL-CURRENT: 424/178.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/153.1,  
424/173.1, 424/184.1, 530/350, 530/387.1, 530/387.3, 530/388.1, 530/388.2,  
530/388.22, 530/388.73

Full	Title	Classification	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------------	-------	--------	----------------	------	-----------	-----------	-------------

Title	Draw Desc	Image
-------	-----------	-------

☒ 17. Document ID: US 6004552 A

L6: Entry 17 of 23

File: USPT

Dec 21, 1999

US-PAT-NO: 6004552

DOCUMENT-IDENTIFIER: US 6004552 A

TITLE: Methods of blocking B cell proliferation using anti-CD40 monoclonal antibodies

DATE-ISSUED: December 21, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
de Boer; Mark	Beuerwyk			NL
Conroy; Leah B	Pacifica	CA		

US-CL-CURRENT: 424/144.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/153.1,  
424/173.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 18. Document ID: US 6001358 A

L6: Entry 18 of 23

File: USPT

Dec 14, 1999

US-PAT-NO: 6001358

DOCUMENT-IDENTIFIER: US 6001358 A

TITLE: Humanized antibodies to human gp39, compositions containing thereof

DATE-ISSUED: December 14, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Black; Amelia	Cardiff	CA		
Hanna; Nabil	Olivenhian	CA		
Padlan; Eduardo A.	Kensington	MD		
Newman; Roland A.	San Diego	CA		

US-CL-CURRENT: 424/154.1; 424/130.1, 424/133.1, 424/141.1, 424/143.1, 424/144.1,  
424/153.1, 424/173.1, 530/387.1, 530/387.3, 530/388.1, 530/388.2, 530/388.22,  
530/388.7, 530/388.73, 530/388.75, 536/23.53

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 19. Document ID: US 5962224 A

L6: Entry 19 of 23

File: USPT

Oct 5, 1999

US-PAT-NO: 5962224

DOCUMENT-IDENTIFIER: US 5962224 A

TITLE: Isolated DNA encoding p62 polypeptides and uses therefor

DATE-ISSUED: October 5, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shin; Jaekyoon	Westwood	MA		
Joung; Insil	Boston	MA		
Vadlamudi; Ratna K.	Norwood	MA		
Strominger; Jack L.	Lexington	MA		

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/366, 435/69.1, 435/70.1, 536/23.1,  
536/24.31, 536/24.33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 20. Document ID: US 5912141 A

L6: Entry 20 of 23

File: USPT

Jun 15, 1999

US-PAT-NO: 5912141

DOCUMENT-IDENTIFIER: US 5912141 A

TITLE: Nucleic acids encoding tumor virus susceptibility genes

DATE-ISSUED: June 15, 1999

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Brojatsch; Jurgen	Jamaica Pond	MA		
Naughton; John	Somerville	MA		
Young; John A. T.	Auburndale	MA		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/254.11, 435/320.1, 435/325, 435/69.7,  
530/300, 530/350, 530/826, 536/23.1, 536/23.4, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

Keyword	Draw Desc	Image
---------	-----------	-------

Generate Collection

Print

Term	Documents
CD40L.DWPI,EPAB,USPT.	251
CD40LS.DWPI,EPAB,USPT.	2
CD40.DWPI,EPAB,USPT.	956
CD40S	0
LIGAND.DWPI,EPAB,USPT.	56962
LIGANDS.DWPI,EPAB,USPT.	40379
GP39.DWPI,EPAB,USPT.	145
GP39S	0
SOLUBLE.DWPI,EPAB,USPT.	447337
SOLUBLES.DWPI,EPAB,USPT.	4183
ITP.DWPI,EPAB,USPT.	670
((CD40L OR CD40 ADJ LIGAND OR GP39)SAME (SOLUBLE) AND (INHIBIT\$ OR SUPPRESS\$ OR BLOCK\$ OR PREVENT\$ OR TREAT\$ OR THERAP\$) SAME (ITP OR THROMBOCYTOPENIA OR PURPURA)).USPT,EPAB,DWPI.	23

There are more results than shown above. [Click here to view the entire set.](#)

Display Format:

-

Change Format

[Previous Page](#)[Next Page](#)

expensive treatment, cannot be recommended for **alloimmunized** adults with leukemia.

12/7/4 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

05269416 87020965 PMID: 3765548

Hematologic disorders.

Harrington W

Vox sanguinis (SWITZERLAND) 1986, 51 Suppl 2 p18-21, ISSN 0042-9007

Journal Code: 0413606

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

A distinction is made between postinfection thrombocytopenia of childhood and idiopathic thrombocytopenia (ITP) of adulthood. Relative advantages of treatment modalities, including splenectomy, are weighed, with an emphasis on the administration of intravenous immunoglobulin (IVIG) as an emergency measure in the adult patient with ITP. Management of thrombotic thrombocytopenic purpura (TTP) is also discussed, as is the case of a patient who became **alloimmunized** after 2 years of multiple transfusions used to treat an arteriovenous malformation of the small bowel.

Record Date Created: 19861114

? ds

Set	Items	Description
S1	114	(CD40 OR CD40L OR CD40(W)LIGAND OR 5C8 OR GP39) AND TRANSFUSION
S2	72	RD S1 (unique items)
S3	7	S2 AND PY<1998
S4	0	S1 AND ITP
S5	3	S1 AND PURPURA
S6	1	RD S5 (unique items)
S7	34	(ITP OR IDIOTYPIC(W)THROMBOCYTOPENIA) (10N) (TRANSFUSION) (10-N) (PLATELET?)
S8	24	RD S7 (unique items)
S9	2	S8 AND ALLOIMMUNI?
S10	2	RD S9 (unique items)
S11	6	(ITP OR IDIOTYPIC(W)THROMBOCYTOPENIA) AND (TRANSFUSION) (10-N) (PLATELET?) AND ALLOIMMUNI?
S12	4	RD S11 (unique items)
?		

GHT set on as ' '  
? begin 5,73,155,399  
06nov02 18:11:14 User208760 Session D2201.2  
\$0.00 0.071 DialUnits File410  
\$0.00 Estimated cost File410  
\$0.01 TELNET  
\$0.01 Estimated cost this search  
\$0.30 Estimated total session cost 0.154 DialUnits

SYSTEM:OS - DIALOG OneSearch  
File 5:Biosis Previews(R) 1969-2002/Oct W4  
(c) 2002 BIOSIS  
\*File 5: Alert feature enhanced for multiple files, duplicates  
removal, customized scheduling. See HELP ALERT.  
File 73:EMBASE 1974-2002/Oct W4  
(c) 2002 Elsevier Science B.V.  
\*File 73: Alert feature enhanced for multiple files, duplicates  
removal, customized scheduling. See HELP ALERT.  
File 155:MEDLINE(R) 1966-2002/Nov W1  
\*File 155: Alert feature enhanced for multiple files, duplicates  
removal, customized scheduling. See HELP ALERT.  
File 399:CA SEARCH(R) 1967-2002/UD=13719  
(c) 2002 American Chemical Society  
\*File 399: Use is subject to the terms of your user/customer agreement.  
Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set	Items	Description
---	-----	-----
? s	(cd40 or cd40L or cd40(w)ligand or 5c8 or gp39) and transfusion	
	16052	CD40
	4074	CD40L
	16052	CD40
	326444	LIGAND
	7229	CD40(W)LIGAND
	104	5C8
	555	GP39
	138251	TRANSFUSION
S1	114	(CD40 OR CD40L OR CD40(W)LIGAND OR 5C8 OR GP39) AND TRANSFUSION
? rd s1		
	...examined 50 records	(50)
	...examined 50 records	(100)
	...completed examining records	
	S2	72 RD S1 (unique items)
? s s2 and py<1998		
Processing		
Processing		
	72	S2
	42267915	PY<1998
	S3	7 S2 AND PY<1998
? t s3/3/all		

3/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

11243900 BIOSIS NO.: 199800025232  
Blockade of **CD40L/CD40** costimulatory pathway in a DST  
pre-sensitization model leads to a state of allo-Ag specific anergy and  
permits prolong islet allograft survival.  
AUTHOR: Zheng X X; Roy-Chaudhy P; Li Y; Nickerson P; Tian Y; Li X C; Zand M  
; Sayegh M; Strom T B  
AUTHOR ADDRESS: Beth Israel Deaconess Med. Cent., Brigham Women's Hosp.,  
Harvard Med. Sch., Boston\*\*USA



JOURNAL: Journal of the American Society of Nephrology 9 (PROGRAM AND  
ABSTR. ISSUE):p670A Sept., 1997  
CONFERENCE/MEETING: 30th Annual Meeting of the American Society of  
Nephrology San Antonio, Texas, USA November 2-5, 1997  
SPONSOR: American Society of Nephrology  
ISSN: 1046-6673  
RECORD TYPE: Citation  
LANGUAGE: English

3/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

11086413 BIOSIS NO.: 199799707558  
Prolonged survival of mouse skin allografts in recipients treated with  
donor splenocytes and antibody to **CD40 ligand**.  
AUTHOR: Markees Thomas G; Phillips Nancy E; Noelle Randolph J; Shultz  
Leonard D; Mordes John P; Greiner Dale L; Rossini Aldo A(a)  
AUTHOR ADDRESS: (a)Diabetes Div., Univ. Mass. Med. Sch., Biotech 2, 373  
Plantation Street, Suite 218, Worcester, MA\*\*USA  
JOURNAL: Transplantation (Baltimore) 64 (2):p329-335 1997  
ISSN: 0041-1337  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

10289337 BIOSIS NO.: 199698744255  
Induction of immunological tolerance to islet allografts.  
AUTHOR: Rossini Aldo A(a); Parker David C; Phillips Nancy E; Durie Fiona H;  
Noelle Randolph J; Mordes John P; Greiner Dale L  
AUTHOR ADDRESS: (a)Diabetes Div., Univ. Mass. Med. Sch., Biotech II, Suite  
218, 373 Plantation St., Worcester, MA 0\*\*USA  
JOURNAL: Cell Transplantation 5 (1):p49-52 1996  
ISSN: 0963-6897  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

10091477 BIOSIS NO.: 199598546395  
Survival of mouse pancreatic islet allografts in recipients treated with  
allogeneic small lymphocytes and antibody to **CD40 ligand**.  
AUTHOR: Parker David C; Greiner Dale L; Phillips Nancy E; Appel Michael C;  
Steele Alan W; Durie Fiona H; Noelle Randolph J; Mordes John P; Rossini  
Aldo A(a)  
AUTHOR ADDRESS: (a)Diabetes Div., 373 Plantation St., Suite 218, Worcester,  
MA 01605\*\*USA  
JOURNAL: Proceedings of the National Academy of Sciences of the United  
States of America 92 (21):p9560-9564 1995  
ISSN: 0027-8424  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

3/3/5 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)

09204930 97098504 PMID: 8943044

Costimulatory function and expression of **CD40 ligand**, CD80, and CD86 in vascularized murine cardiac allograft rejection.

Hancock W W; Sayegh M H; Zheng X G; Peach R; Linsley P S; Turka L A  
Department of Pathology, New England Deaconess Hospital, Boston, MA 02215, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Nov 26 1996, 93 (24) p13967-72, ISSN

0027-8424 Journal Code: 7505876

Contract/Grant No.: AI-34965; AI; NIAID; AI-37691; AI; NIAID

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

3/3/6 (Item 2 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)

08848438 96199655 PMID: 8623413

Tolerance to islet xenografts induced by dual manipulation of antigen presentation and co-stimulation.

Markees T G; Appel M C; Noelle R J; Mordes J P; Greiner D L; Rossini A A  
Diabetes Division, University of Massachusetts Medical School, Worcester 01605, USA.

Transplantation proceedings (UNITED STATES) Apr 1996, 28 (2) p814-5, ISSN 0041-1345 Journal Code: 0243532

Contract/Grant No.: DK25306; DK; NIDDK; DK36024; DK; NIDDK; DK41235; DK; NIDDK; +

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

3/3/7 (Item 3 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)

08625470 95383668 PMID: 7544649

Antibodies to **CD40** prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.

Murphy W J; Funakoshi S; Beckwith M; Rushing S E; Conley D K; Armitage R J; Fanslow W C; Rager H C; Taub D D; Ruscetti F W; et al

Biological Carcinogenesis and Development Program, Inc/DynCorp, NCI-FCRDC, MD 21702-1201, USA.

Blood (UNITED STATES) Sep 1 1995, 86 (5) p1946-53, ISSN

0006-4971 Journal Code: 7603509

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

? t s3/kwic/all

>>>KWIC option is not available in file(s): 399

3/KWIC/1 (Item 1 from file: 5)  
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

Blockade of **CD40L/CD40** costimulatory pathway in a DST pre-sensitization model leads to a state of allo-Ag...

1997

METHODS & EQUIPMENT: donor specific **transfusion**--  
MISCELLANEOUS TERMS: ...**CD40L/CD40** costimulatory pathway

3/KWIC/2 (Item 2 from file: 5)  
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to **CD40 ligand**.

1997

ABSTRACT: Combined treatment with antibody against **CD40 ligand** and one **transfusion** of donor splenocytes prolonged survival of fully mismatched BALB/c skin allografts on C57BL/6...

...100 days revealed no evidence of lymphoid chimerism. Treatment with donor splenocytes and antibody against **CD40 ligand** permits long-term survival of highly antigenic donor skin allografts despite the presence of functionally...

MISCELLANEOUS TERMS: ...**CD40 LIGAND**;

3/KWIC/3 (Item 3 from file: 5)  
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

1996

ABSTRACT: T-cell dependent activation of resting B cells involves the interaction of **gp39** on T cells with its receptor, **CD40**, on B cells. We administered either a combination of T-cell-depleted splenic lymphocytes and...

...Antibody alone was less effective in prolonging allograft survival, but we did observe that anti-**gp39** mAb alone can exert an independent, primary effect on islet allograft survival that was dose dependent. Targeting **gp39**, in combination with lymphocyte **transfusion**, might prove suitable for tolerance induction and allotransplantation without immunosuppression.

MISCELLANEOUS TERMS: ANTI-**GP39** ANTIBODY...

3/KWIC/4 (Item 4 from file: 5)  
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

...of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to **CD40 ligand**.

1995

...ABSTRACT: treatment with allogeneic small lymphocytes or T-depleted small lymphocytes plus a blocking antibody to **CD40 ligand** (**CD40L**) permitted indefinite pancreatic islet allograft survival in 37 of 40 recipients that differed from islet...

...was donor antigen-specific. Neither treatment alone was as effective as combined treatment, although anti-**CD40L** by itself allowed indefinite islet allograft survival in 40% of recipients. Our interpretation is that...

...antigens in the absence of appropriate costimulatory signals are tolerogenic for alloreactive host cells. Anti-**CD40L** antibody may prevent host T cells from inducing costimulatory signals in donor lymphocytes or islet...

MISCELLANEOUS TERMS: ...LYMPHOCYTE **TRANSFUSION**;

3/KWIC/5 (Item 1 from file: 155)  
DIALOG(R)File 155:

Costimulatory function and expression of **CD40 ligand**, CD80, and CD86 in vascularized murine cardiac allograft rejection.

Nov 26 1996,

Recent data implicates a role for the **CD40-CD40 ligand (CD40L)** pathway in graft rejection. One potential mechanism is direct costimulation of T cells through **CD40L**. Alternatively, the ability of **CD40** stimulation to induce CD80 (B7-1) and CD86 (B7-2) expression on antigen-presenting cells (APCs) has led to the hypothesis that the role of **CD40-CD40L** interactions in transplant rejection might be indirect, i.e., to promote the costimulatory capacity of ...

... this hypothesis. Treatment of the recipients with donor splenocytes and a single dose of anti-**CD40L** mAb induces long-term graft survival (> 100 days) in all animals. This is associated with...

... 24 hr. In contrast, CD80 expression is not seen until 72 hr after engraftment. Anti-**CD40L** mAb has no detectable effect on CD86 up-regulation, but almost completely abolishes induction of...

... indicating that blockade of CD80 alone does not mediate the graft-prolonging effects of anti-**CD40L** mAb. These data support the notion that the role of **CD40-CD40L** in transplant rejection is not solely to promote CD80 or CD86 expression, but rather that...

; Antibodies, Monoclonal; Antigen-Presenting Cells--immunology--IM; Antigens, Differentiation, T-Lymphocyte--biosynthesis--BI; **CD40 Ligand**; Coronary Circulation; Cytokines--biosynthesis--BI; Graft Rejection--pathology--PA; Heart Transplantation--pathology--PA; Lymphocyte **Transfusion**; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Transplantation, Homologous

...Chemical Name: Monoclonal; Antigens, CD; Antigens, CD80; Antigens, Differentiation, T-Lymphocyte; B7-2 protein; Cytokines; Membrane Glycoproteins; **CD40 Ligand**

3/KWIC/6 (Item 2 from file: 155)  
DIALOG(R)File 155:

Apr 1996,

...Descriptors: SU; \*Graft Survival--immunology--IM; \*Immunosuppression --methods--MT; \*Islets of Langerhans Transplantation--immunology--IM; \*Lymphocyte **Transfusion**; \*Membrane Glycoproteins--immunology--IM; \*Skin Transplantation--immunology--IM; \*Transplantation, Heterologous --immunology--IM; Antigens, **CD40**; **CD40 Ligand**; Graft Survival--drug effects--DE; Mice; Mice, Inbred C57BL; Rats; Rats, Inbred Lew; Spleen--immunology...

Chemical Name: Antibodies, Monoclonal; Antigens, **CD40**; Membrane Glycoproteins; **CD40 Ligand**

3/KWIC/7 (Item 3 from file: 155)  
DIALOG(R)File 155:

Antibodies to **CD40** prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice...

Sep 1 1995,

**CD40** is expressed on both normal and neoplastic B lymphocytes. Signal transduction through **CD40** in vitro has been shown to exert stimulatory effects on normal B cells and inhibitory...

... transplantation or in the setting of immunodeficiency. Treatment of huPBL-SCID chimeric mice with anti-CD40 or anti-CD20 monoclonal antibodies (MoAb) significantly delayed the development of EBV-induced B-cell lymphoma. However, the effects of the two MoAb were mechanistically distinct. Anti-CD40 treatment prevented lymphoma generation, while still allowing for functional human B-cell engraftment in the...

... vitro assays examining the transformation of human B cells by EBV also indicated that anti-CD40 could directly inhibit EBV-transformation, whereas anti-CD20 antibodies had no effect. Thus, anti-CD40 exerts selective effects to allow for the engraftment of normal human B cells and prevent the emergence of EBV lymphomas. Stimulation of CD40 by antibodies or its physiologic ligand may, therefore, be of significant clinical use in the...

...Descriptors: B-Lymphocyte--immunology--IM; \*B-Lymphocytes--immunology--IM; \*Cell Transformation, Neoplastic; \*Herpesvirus 4, Human; \*Lymphocyte Transfusion; \*Lymphoma, B-Cell--immunology--IM; Antigens, CD20; Antigens, CD40; Diphtheria Toxin--immunology--IM; Enzyme-Linked Immunosorbent Assay; HLA Antigens--analysis--AN; HLA-DR Antigens...

Chemical Name: Antibodies, Monoclonal; Antigens, CD; Antigens, CD20; Antigens, CD40; Antigens, Differentiation, B-Lymphocyte; Diphtheria Toxin; HLA Antigens; HLA-DR Antigens; Immunoglobulins; Tetanus Toxin  
? ds

```
Set      Items  Description
S1        114   (CD40 OR CD40L OR CD40(W)LIGAND OR 5C8 OR GP39) AND TRANSF-
              USION
S2         72   RD S1 (unique items)
S3          7   S2 AND PY<1998
? s s1 and itp
          114   S1
          8065  ITP
          S4      0   S1 AND ITP
? s s1 and purpura
          114   S1
          35976  PURPURA
          S5      3   S1 AND PURPURA
? rd s5
...completed examining records
          S6      1   RD S5 (unique items)
? t s6/3/all
```

6/3/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13183747 BIOSIS NO.: 200100390896  
Porcine hematopoietic cell xenotransplantation in nonhuman primates is complicated by thrombotic microangiopathy.  
AUTHOR: Buhler L; Goepfert C; Kitamura H; Basker M; Gojo S; Alwayn I P J; Chang Q; Down J D; Tsai H; Wise R; Sachs D H; Cooper D K C; Robson S C; Sackstein R(a)  
AUTHOR ADDRESS: (a)Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Room 671, Boston, MA, 02115\*\*USA  
JOURNAL: Bone Marrow Transplantation 27 (12):p1227-1236 June 2, 2001  
MEDIUM: print  
ISSN: 0268-3369  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
? t s6/kwic/all  
>>>KWIC option is not available in file(s): 399

6/KWIC/1 (Item 1 from file: 5)  
DIALOG(R)File 5:(c) 2002 BIOSIS. All rts. reserv.

...ABSTRACT: microangiopathy (TM) is a serious complication of bone marrow transplantation (BMT) that resembles thrombotic thrombocytopenic **purpura** (TTP). In attempting to achieve hematopoietic cell chimerism in the pig-to-baboon model, we...

...PBPC TX combined with prostacyclin, low-dose heparin, methylprednisolone, and cyclosporine was replaced by anti-**CD40L** mAb in five cases. Baboons in groups 1 and 3 developed severe thrombocytopenia (<10 000...

...in plasma lactate dehydrogenase (LDH) (2500-9000 U/l), transient neurologic changes, renal insufficiency, and **purpura**. Autopsy on two baboons confirmed extensive platelet thrombi in the microcirculation, and, similar to clinical...

...15 days following NMR. Group 4 baboons developed thrombocytopenia (<20 000/mm3) rarely requiring platelet **transfusion**, minimal schistocytosis (<3/hpf), minor increase in LDH (<1000 U/l), with no clinical sequelae...

DESCRIPTORS:

...DISEASES: thrombotic thrombocytopenic **purpura**--  
ALTERNATE INDEXING: **Purpura**, Thrombotic Thrombocytopenic (MeSH)  
? s (itp or idiotypic(w)thrombocytopenia) (10n) (transfusion) (10n)platelet?)  
>>>Unmatched parentheses  
? s (itp or idiotypic(w)thrombocytopenia) (10n) (transfusion) (10n) (platelet?)  
8065 ITP  
23106 IDIOTYPIC  
74619 THROMBOCYTOPENIA  
0 IDIOTYPIC(W)THROMBOCYTOPENIA  
138251 TRANSFUSION  
418430 PLATELET?  
S7 34 (ITP OR  
IDIOTYPIC(W)THROMBOCYTOPENIA) (10N) (TRANSFUSION) (10N) (PLA-  
TELET?)

? rd s7  
...completed examining records  
S8 24 RD S7 (unique items)  
? s s8 and alloimmuni?)  
>>>Unmatched parentheses  
? s s8 and alloimmuni?  
24 S8  
6274 ALLOIMMUNI?  
S9 2 S8 AND ALLOIMMUNI?  
? rd s9  
...completed examining records  
S10 2 RD S9 (unique items)  
? t s10/7/all

10/7/1 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

10742815 EMBASE No: 2000223321

Refractoriness to **platelet transfusion** following double valve replacement in an **ITP** patient who had undergone splenectomy  
Kaneda T.; Ku K.; Oku H.; Inoue T.; Matsumoto T.; Onoe M.; Kitayama H.; Iemura J.; Nakamoto S.; Oka H.; Otaki M.

Dr. T. Kaneda, Department of Cardiovascular Surgery, Kinki University School of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka 589-8511 Japan

Journal of Cardiac Surgery ( J. CARD. SURG. ) (United States) 1999, 14/5

(386-389)  
CODEN: JCASE ISSN: 0886-0440  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 22

Reports of patients with idiopathic thrombocytopenic purpura (ITP) undergoing cardiac surgery are rare, and almost all of the reported cases required **platelet transfusion**. ITP patients, especially those having a history of splenectomy or a history of heavy bleeding, may have to undergo multiple **platelet** transfusions. Such transfusions may induce **alloimmunization** against the human leukocyte antigen (HLA) and result in refractoriness to subsequent platelet transfusions. We report a case of a 63-year-old female with ITP, with a history of splenectomy and multiple platelet transfusions, who underwent aortic and mitral valve replacement. Although corticosteroid administration, high-dose immunoglobulin therapy, and repeated platelet transfusion led to a temporary increase in platelet count and successful hemostasis, refractoriness to platelet transfusion occurred postoperatively because of the presence of the anti-HLA antibody. In addition, the patient showed complications of pyothorax. Corticosteroids might have exerted an inhibitory influence on the occurrence of pyothorax.

10/7/2 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

02559607 EMBASE No: 1984228462  
High-dose intravenous gammaglobulin in **alloimmunized** platelet transfusion recipients  
Schiffer C.A.; Hogge D.E.; Aisner J.; et al.  
Cell Component Therapy Section, Division of Hematologic Malignancies,  
University of Maryland Cancer Center, Baltimore, MD United States  
Blood ( BLOOD ) (United States) 1984, 64/4 (937-940)  
CODEN: BLOOA  
DOCUMENT TYPE: Journal  
LANGUAGE: ENGLISH

High-dose intravenous gammaglobulin (polyvalent immunoglobulin G) has been shown to be of benefit in some patients with immune thrombocytopenic purpura (ITP), possibly by producing reticuloendothelial system blockade. We studied this approach in patients refractory to random donor **platelet transfusion** using an IV IgG preparation manufactured by the Swiss Red Cross. Eleven adult patients with acute leukemia received either 0.4 g IgG/kg/d intravenously x five days (four patients) or 0.6 g/kg/d x five days (seven patients). All patients had high levels of lymphocytotoxic antibody and poor responses to random donor platelets. Except for mild headaches in two patients, there were no side effects related to the IgG infusions. All patients had significant elevations of serum IgG on the day after completion of treatment. Either random donor or partially HLA-matched platelet transfusions were administered the day after and, in some cases, during the IgG therapy. No patient had an improvement in one hour posttransfusion platelet count increments. Two additional patients received pooled platelet concentrations incubated for 30 minutes at 37degree C with IgG at a final concentration of 3 g% prior to transfusions. These results indicate that high-dose IgG, an extremely expensive treatment, cannot be recommended for **alloimmunized** adults with leukemia.

? s (itp or idiotypic(w)thrombocytopenia) and (transfusion)(10n)(platelet?) and alloimmuni?

8065 ITP  
23106 IDIOTYPIC  
74619 THROMBOCYTOPENIA

```

      0 IDIOTYPIC(W)THROMBOCYTOPENIA
138251 TRANSFUSION
418430 PLATELET?
      9631 TRANSFUSION(10N)PLATELET?
      6274 ALLOIMMUNI?
S11      6 (ITP OR IDIOTYPIC(W)THROMBOCYTOPENIA) AND
          (TRANSFUSION)(10N)(PLATELET?) AND ALLOIMMUNI?

```

? rd s11

...completed examining records

```

      S12      4 RD S11 (unique items)

```

? t s12/7/all

```

12/7/1      (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

```

```

10991984      EMBASE No: 2001038681
Thrombocytopenia and critical care medicine
Gelinas J.-P.; Stoddart L.V.; Snyder E.L.
Dr. E.L. Snyder, Blood Bank CB-459, Yale-New Haven Hospital, 20 York St,
New Haven, CT 06504 United States
AUTHOR EMAIL: edward.snyder@yale.edu
Journal of Intensive Care Medicine ( J. INTENSIVE CARE MED. ) (United
States) 2001, 16/1 (1-21)
CODEN: JICME ISSN: 0885-0666
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 155

```

Platelet transfusions play an important role in the treatment of critically ill patients. Like any blood component, however, there are various aspects of **platelet transfusion** therapy that need be considered by the intensivist. These include the proper dose and type of platelet component to infuse, as well as the route and method of administration. Methods to reduce the volume of the transfused platelets, for example, must ensure that the infused platelets will be functional and viable, posttransfusion. Treatment and diagnosis of the HLA **alloimmunized** recipient can pose a serious challenge to the clinician and an obstacle to adequate platelet therapy. An ICU patient for whom an adequate posttransfusion platelet increment cannot be achieved is at great risk of suffering a fatal hemorrhage. The ICU physician should be aware of the techniques used in modern transfusion practice to avoid having to deal with this complication. Adverse reactions to **platelet transfusion** include not only serologic ones, but those related to febrile and allergic complications, as well as infectious complications. The latter group includes diseases caused by infection with cytomegalovirus, bacteria, and a cadre of viruses including HIV and hepatitis. The clinical approach to thrombocytopenia in tile ICU will be covered in some detail in an effort to review many of the conditions associated with recipient thrombocytopenia, including **ITP**. TTP, dilutional thrombocytopenia. DIC, surgery, HELLP syndrome, and drug-induced thrombocytopenia. Unfortunately the treatment approaches traditionally used are not always derived from evidence-based studies. This review covers many of these topics in an attempt to help physicians become better able to manage thrombocytopenia in the ICU and thus provide the best transfusion therapy for their patients.

```

12/7/2      (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

```

```

10742815      EMBASE No: 2000223321
Refractoriness to platelet transfusion following double valve

```



replacement in an **ITP** patient who had undergone splenectomy

Kaneda T.; Ku K.; Oku H.; Inoue T.; Matsumoto T.; Onoe M.; Kitayama H.; Iemura J.; Nakamoto S.; Oka H.; Otaki M.

Dr. T. Kaneda, Department of Cardiovascular Surgery, Kinki University School of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka 589-8511 Japan

Journal of Cardiac Surgery ( J. CARD. SURG. ) (United States) 1999, 14/5 (386-389)

CODEN: JCASE ISSN: 0886-0440

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 22

Reports of patients with idiopathic thrombocytopenic purpura (**ITP**) undergoing cardiac surgery are rare, and almost all of the reported cases required **platelet transfusion**. **ITP** patients, especially those having a history of splenectomy or a history of heavy bleeding, may have to undergo multiple platelet transfusions. Such transfusions may induce **alloimmunization** against the human leukocyte antigen (HLA) and result in refractoriness to subsequent platelet transfusions. We report a case of a 63-year-old female with **ITP**, with a history of splenectomy and multiple platelet transfusions, who underwent aortic and mitral valve replacement. Although corticosteroid administration, high-dose immunoglobulin therapy, and repeated **platelet transfusion** led to a temporary increase in **platelet** count and successful hemostasis, refractoriness to **platelet transfusion** occurred postoperatively because of the presence of the anti-HLA antibody. In addition, the patient showed complications of pyothorax. Corticosteroids might have exerted an inhibitory influence on the occurrence of pyothorax.

12/7/3 (Item 3 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

02559607 EMBASE No: 1984228462

High-dose intravenous gammaglobulin in **alloimmunized platelet transfusion** recipients

Schiffer C.A.; Hogge D.E.; Aisner J.; et al.

Cell Component Therapy Section, Division of Hematologic Malignancies, University of Maryland Cancer Center, Baltimore, MD United States

Blood ( BLOOD ) (United States) 1984, 64/4 (937-940)

CODEN: BLOOA

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH

High-dose intravenous gammaglobulin (polyvalent immunoglobulin G) has been shown to be of benefit in some patients with immune thrombocytopenic purpura (**ITP**), possibly by producing reticuloendothelial system blockade. We studied this approach in patients refractory to random donor **platelet transfusion** using an IV IgG preparation manufactured by the Swiss Red Cross. Eleven adult patients with acute leukemia received either 0.4 g IgG/kg/d intravenously x five days (four patients) or 0.6 g/kg/d x five days (seven patients). All patients had high levels of lymphocytotoxic antibody and poor responses to random donor platelets. Except for mild headaches in two patients, there were no side effects related to the IgG infusions. All patients had significant elevations of serum IgG on the day after completion of treatment. Either random donor or partially HLA-matched platelet transfusions were administered the day after and, in some cases, during the IgG therapy. No patient had an improvement in one hour posttransfusion platelet count increments. Two additional patients received pooled platelet concentrations incubated for 30 minutes at 37degree C with IgG at a final concentration of 3 g% prior to transfusions. These results indicate that high-dose IgG, an extremely